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Summary 
                 Lactobacilli are attractive candidates for vaccine delivery vehicles 
because they are considered as GRAS (Generally regarded as safe) organisms with 
a very long record of safe oral consumption. They have greater intrinsic 
immunogenicity and colonizing ability in the GI tract that make them potentially 
better candidates for vaccination. The health promoting effects of Lactobacillus 
rhamnosus GG have also been studied extensively; however it has been poorly 
exploited as a vaccine delivery vehicle. This dissertation aims to characterize LGG 
as vaccine delivery vehicle.  Mucosal immunization with LGG expressing GFP or 
IL2-GFP induced GFP specific serum IgG and IgA. The fusion of IL2 to GFP 
resulted in significantly increased GFP specific serum IgA and IgG and SIgA titers 
compared to LGG-GFP immunization. Immunization in nasal route showed no 
abnormal lung damage though increased cellular infiltration was seen initially and 
subsequently reverted close to normal. Immunohistochemical staining of the lung 
tissue showed IgA producing B cells at 80th day of post primary immunization. 
There were increased GFP specific CD8 T cells in the recall assay which was 
significantly increased by IL2- GFP mucosal delivery.   
                Members of γc cytokine family (IL7, IL15 and IL2) have been 
expressed with PSA in LGG and co-cultured in vitro with DC or neutrophils to 
study the antigen presentation. LGG itself have stimulatory effects on DC 
maturation and increased the expression of CD86, CD80, CD40 and MHC II.  
IL15-PSA or IL2–PSA secreting LGG reduced IL10 production by DC, IL7 did 
not, but all three resulted in increased IL12p70 production. However, the T cell 
response did not correlate with differences in IL12 or IL10 production. 
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LGG-S-IL15-PSA treated DC primed T cells showed high IFNγ production and 
CTL response on target cells indicating efficient antigen presentation to T cells. 
LGG treated neutrophils did not induce any of the co-stimulatory molecules or 
MHC II expression but only showed elevated expression of the MHC I molecules. 
LGG treated neutrophils produced high and moderate levels of IL10 and IL12p70 
respectively and efficiently induced allogeneic T cell proliferation.  LGG treated 
neutrophils increased the expression of co-stimulatory molecules on DC that 
clearly showed bacteria treated neutrophils could deliver the maturation signals to 
immature DC. Recombinant LGG treated neutrophils provided antigen specificity 
to DC by unknown mechanism when it was co-cultured with DC and also rendered 
a cytotoxic effect in T cell presentation. This ensures the efficacy of LGG based 
antigen delivery in inducing immune response through neutrophils alone in the 
absence of direct bacteria-DC encounter. This dissertation showed that LGG as a 
promising antigen delivery vehicle and that IL15 is a good vaccine adjuvant 
especially when administered as fusion protein with antigen. 
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1.1. Mucosal immune system - An Overview 
The mammalian mucosal immune system consists of a network of lymphoid 
tissues which frequently encounters foreign invaders at mucosal surfaces. The 
mucosal surface is the major portal of entry for infectious agents and it has a vast 
and enormous surface area, approximately 300 to 400 m2. This requires a 
formidable defence system mainly contributed by the Mucosa Associated 
Lymphoid Tissue (MALT) through secretory IgA and effector T cells that act 
synergistically with the innate immune system (Fujihashi et al. 2008). The 
mucosa contains the highest lymphocyte concentration, approximately about 6 x 
1010 antibody-forming cells in MALT compared to 2.5 x 1010 lymphocytes in the 
lymphoid organs. The main components of MALT are Gut Associated Lymphoid 
Tissue (GALT), Bronchus Associated Lymphoid Tissue (BALT) and 
Nasopharyngeal Associated Lymphoreticular Tissue (NALT). The GALT is 
comprised of the Peyer’s patches (PP), the appendix, and the solitary lymphoid 
nodules. The tonsils and adenoids (human) or nasal associated lymphoreticular 
tissue comprise the NALT (Staats et al. 1996).  
 Most human pathogens enter the body through a mucosal surface, such as the 
intestine, and strong immune responses are required to protect this 
physiologically essential tissue. However active immunity against non-
pathogenic materials would be dangerous and lead to inflammatory disorders 
such as Coeliac disease and Crohn’s disease. As a result, the usual response to 
harmless gut antigens is the induction of local and systemic immunological 
tolerance, known as oral tolerance (Strobel et al. 1998).  The intestinal microflora 
play important roles in the modulation of oral tolerance (Moreau and Corthier et 
al, 1988). Administration of probiotics could restore oral tolerance in germfree 
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mice, and those effects are strain-dependent (Maeda et al. 2001). Immune 
tolerance in Lactobacilli administration may be avoided by choosing specific 
strain that induces Th1 rather than Th2 immune response (Drago et al. 2010) 
SED
 
 Figure 1.1   Schementic  representation of  gut associated lymphoid tissue          
(GALT)  
Peyer's patches are composed of a specialized follicle-associated epithelium 
(FAE) containing M cells, a subepithelial dome (SED) rich in dendritic cells 
(DCs), B and T lymphocytes.  
 
1.1.1. Peyer’s patches  (PP) 
The PP germinal centres in the gastrointestinal tract are the major sites for 
frequent B cell switches to IgA (Lebman et al. 1987; Butcher et al. 1982). 
Peyer’s patches are one of the major sources of IgA plasma cell precursors that 
undergo direct antigen driven proliferation. After antigenic stimulation, IgA+ 
lymphoblasts migrate through the lymph and blood circulation and eventually 
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home in to the lamina propria of the intestine. Mature Peyer’s patches consist of 
collections of large B-cell follicles and intervening T-cell areas. The lymphoid 
areas are separated from the intestinal lumen by a single layer of columnar 
epithelial cells, known as the follicle-associated epithelium (FAE) and the most 
notable feature of FAE is the presence of microfold cells (M) cells, which are 
specialized enterocytes that lack surface microvilli and the thick layer of mucus 
(Mowat et al. 2003). M cells serve as portals of entry for pathogens (Jones et al. 
1994) and are known to internalize and transport luminal antigens into the 
underlying lymphoid tissue (Wolf and Bye et al. 1984) where antigen presenting 
cells will acquire the antigens and present them to T cells after processing.  
 
1.1.2. Intestinal enterocytes  
Intestinal enterocytes are also known to process and present antigens (Zimmer et 
al. 2000), but they only induce tolerance since they do not express the co-
stimulatory molecules that are required for full T cell activation (Sanderson et al. 
1993).  However intestinal epithelial cells were reported to express non classical 
restriction elements CD1 and T1 in mouse and CD1d in man (Bleicher et al. 
1990; Blumberg et al. 1991; Panja et al. 1993). These class Ib molecules are 
capable of binding peptides and interestingly non-peptide antigens. Intestinal 
mucosa can discriminate pathogenic and non-pathogenic bacteria which may 
depend on recognition by pattern recognition receptors (PPR). Intestinal 
epithelial cells secrete fluid in response to invasive bacteria (Eckmann et al. 
1997). For non pathogenic bacteria 2 models have been proposed to explain the 
intestinal epithelial cell response. In the first model, Gram negative Escherichia 
coli and certain lactobacilli could trigger a NF-κB mediated inflammatory 
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response which is transient and is suppressed by immune cells which 
predominantly secrete IL-10 in the lamina propria. A second type of response is 
triggered by commensals that do not induce a pro-inflammatory response, but 
evoke the activation of TGF-β which induces tolerance and protects barrier 
integrity (Schiffrin et al. 2002). Recently a receptor mediated antigen uptake 
mechanism involving fetal Fc receptor has been established (Baker et al. 2009). 
This receptor binds IgG by a pH sensitive mechanism that facilitates vesicular 
bidirectional transport of intact-IgG or IgG-antigen complexes across mucosal 
epithelial cells and delivers them to underlying DCs to initiate T cell response 
and alternatively it can deliver IgG antibodies to the mucus lumen for the 
purpose of host defense against epithelial cell-associated pathogens (Yoshida et 
al. 2006).  
 
 1.1.3. Mesenteric lymph nodes (MLN) 
The MLNs are the largest lymph nodes in the body. It is considered as the cross 
roads between the peripheral and mucosal recirculation pathways (systemic 
immune system). Antigen encountered DCs prime the T cells in PP and exit 
through the draining lymphatics to the MLN or prime the T cells in MLN and 
reside for an undefined period for further differentiation. Then they migrate into 
the blood stream through the thoracic duct and finally accumulate in the mucosa 
to give efficient local immune response or tolerance (Mowat et al. 2003).  
  
1.1.4. Mucosal dendritic cells  
Several subsets of DC have been identified in the PP (Iwasaki et al. 2000; 
Johansson   et al. 2005; Kelsall et al. 2005 ). In addition to myeloid (CD8α 
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CD11b+) and lymphoid (CD8α+ CD11b ) subsets another subset (CD8α  
CD11b) was also found at the dome region immediately beneath the FAE.  The 
distinguishable feature of the DC subsets in PP is their ability to secrete IL-10 
rather than IL-12 which is produced by splenic DC in response to activation after 
ligation of the co-stimulatory molecule receptor activator of NF-κb (RANK) 
(Williamson et al. 2002). 
DCs at lamina propria (LP) process the antigen delivered by intestinal 
enterocytes or internalize the organism by extending their cellular processes into 
the lumen after migrating to the epithelial monolayer in the presence of bacteria. 
After processing the antigen, lamina propria DC interact with T cells mainly at 
the MLN rather than in the mucosa itself (Mowat et al. 2003).   
In antigen fed mice, DCs in the MLN produce IL-10 or TGFβ and preferentially 
stimulate antigen specific CD4+ T cells to produce IL-10 and or TGF-β (Akbari 
et al. 2001). This TR1 or TH3 cytokine pattern has been implicated in oral 
tolerance (Groux  et al. 1997). 
 
1.1.5. Mucosal lymphocytes 
The major population of T lymphocytes in intestines are lamina propria T cells, 
intraepithelial T cells and PP T cells. Lamina propria T cells and intraepithelial T 
cells express different pattern of T cell receptor (TCR) and TCRγδ cells are 
distinguished from their TCRαβ cell counterparts by their distinct set of 
somatically rearranged variable (V), diversity (D), joining (J), and constant (C) 
genes. The vast majority of T cells express a TCR composed of an alpha chain 
and a beta chain, whereas a minor T-cell population is characterized by the TCR 
gamma/delta. In contrast to conventional alpha/beta T cells, which are specific 
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for antigenic peptides presented by the major histocompatibility complex, 
gamma/delta T cells directly recognize proteins and even nonproteinacious 
phospholigands. In mice duodenum and jejunum, the intraepithelial T cells are 
present in higher numbers than lamina propria T cells and the distribution of 
TCRαβ cells to TCRγδ cells in intraepithelium is 1:3. In ileum it is reversed to 
3:1.  But the proportion of TCRαβ cells to TCRγδ cells in lamina propria is 
consistent throughout the small intestine at  3:1 (Tamura et al.  2003).  The major 
distribution of TCRαβ cells in lamina propria and the ability of antigen 
recognition by TCRαβ-MHC molecule interaction make lamina propria the main 
site for immune responses to be executed (Tamura et al. 2003). The nonclassical 
class I MHC (class Ib) molecules are recognized by TCRγδ cells and TCRγδ has 
a potential antiviral immune function (Sciammas et al. 1999). Interaction among 
TCRγδ, CD4+ TCRαβ and IgA B cells is reported to be necessary for maximum 
IgA responses (Kiyono et al. 1996)  
 
1.2. Mucosal Vaccines  
Injected vaccines are generally poor inducers of mucosal immunity and therefore 
less effective against mucosal surface infections unlike mucosally administered 
vaccines (Levine et al. 2000; Lamm et al. 1997). Mucosal vaccines induce a 
humoral response at the site of pathogen entry, are easy to administer without the 
need for sterile needles and syringes and thus have the potential for easy mass 
immunization. An important characteristic of the mucosal immune response is 
the local production and secretion of dimeric or multimeric immunoglobulin A 
which are resistant to degradation at the protease rich mucosal surfaces. 
Secretory IgA entraps the antigen or pathogenic microorganism and intercept 
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polymeric immunoglobulin receptor (pIgR) mediated pathogen transport (Lamm 
et al. 1997) 
The antigen specific B cell response to mucosally delivered vaccines is 
dependant on CD4+ Th cells and the frequency of Th1 and Th2 cell responses. In 
particular Th1 cells secreting IFNγ, IL2, and tumor necrosis factor β (TNFβ) are 
less efficient in antibody induction than the Th2 subset.  In the murine system, 
Th1 cells through the secretion of IFNγ are more efficient in the stimulation of 
IgG2a production, whereas Th2 cells producing IL-4 induce IgG1 and IgE 
antibodies (Snapper et al. 1988; Finkelman et al. 1989).  The type of immune 
response induced by immunization determines the efficacy of the vaccine. For 
example, cellular mediated immune responses (CMI) clear intracellular 
pathogens whereas strong antibody responses may be preferable to neutralize the 
effect of bacterial toxins. Vaccine adjuvants or cytokines may be co-administered 
to induce the desired immune response.  
However, with mucosal vaccines the concentration of antigen delivered and 
absorbed in the body or bioavailability of the antigen is poorly characterized. 
Hence, only a few mucosal vaccines have been approved for human use namely, 
oral vaccines against polio virus (Modlin et al. 2004), Salmonella typhi, Vibrio 
cholerae (Levine et al. 2000), rota virus (Kapikian et al. 1996) and nasal 
vaccines against the influenza virus (Belshe et al. 1998).  
The success of mucosal immunization is determined by the following factors: 
1)   Effective delivery of antigen,  
2)  Enhancement of mucosal immune response with immunomodulators or 
adjuvants  
3)  Choice of a regime and  
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4)  Route of mucosal immunization.  
 
Mucosal vaccine- challenges 
In recent years, the use of mucosal vaccines have been given more attention. 
Despite much progress, there are several issues that still need to be addressed.  
1. Mucosal vaccines that are administered orally or intranasally get diluted in 
mucosal secretion and trapped in mucus gel. Relatively larger doses of vaccine 
may be required and it is hard to determine what dose actually crosses the 
mucosal layer. 
2. The most frequently asked question about the mucosal vaccine is the possible 
induction of mucosal tolerance. It is known that repeated oral ingestion of 
antigen results in decreased or totally abrogated responsiveness to subsequent 
systemic immunization with the same antigen. Though some mucosal vaccines 
are intrinsically immunogenic, additional adjuvants like cholera toxin (CT) or 
cytokine co-expression may help to avoid tolerance induction.  
3. Recombinant bacterial vaccines when administered induce immune responses 
against the vaccine antigen initially, but the response to the neo-antigen is 
overwhelmed by response to the more immunodominant antigen of the bacteria 
itself.   
4.  The effectiveness of the live bacterial vaccines is partly dependant on the 
transport to organised lymphoid tissues. Vaccines derived from pathogenic 
microbes like live attenuated S. typhi (Levine et al. 2000) or live attenuated polio 
virus (Modlin et al. 2004) preferentially adhere to M cells and exploit M-cell 
transport to invade organized mucosal lymphoid tissues in the intestines (Jones et 
al. 1994; Sicinski et al. 1990). Lactobacilli are not known to invade lymphoid 
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tissue as the microbes discussed above. However expressing foreign protein with 
DC targeting peptide may improve  bacterial uptake (Mohamadzadeh et al. 
2009). 
5. The important challenge is to apply the results obtained with animal studies to 
clinical trials and to moitor systematically all parameters of the immune 
response.    
 
1.2.1. Live bacterial vaccines   
Both attenuated pathogenic bacteria and commensal microorganisms have been 
successfully used as carriers for vaccine antigens (Thole et al, 2000). Live 
attenuated  pathogens have the double advantage  that  they provide protective 
immunity to the pathogen and also elicit specific immune responses for the 
heterologous antigen that is carried by the pathogen. They also usually colonize 
the mucosae, ensuring prolonged exposure to the immune system for effective 
priming. Thus they do not necessitate repeated administrations. Listeria 
monocytogenes, Salmonella spp., V. cholera, Shigella spp., Mycobacterium bovis 
BCG and Yersinia enterocolitica are successfully used as attenuated mucosal 
pathogens in animal models. Table 1.1 shows the list of some attenuated 
pathogenic bacteria used as vaccine vehicles. Commensal microorganisms, 
Streptococcus gordonii, Lactobacillus spp. and Staphylococcus spp. are also 
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1.2.2. Disadvandages of using attenuated pathogenic bacteria as vaccines 
1. A potential risk of reversion to virulence.  
2.. Doses effective in non-endemic areas may not be effective in endemic areas 
where normal wild type strains are circulating (Detmer et al. 2006).  
 3. Immune induction against the antigen expressed in live bacteria may be 
compromised if the host has pre-existing immunity against carrier strain 
(example - Salmonella). 
 4. Permanent colonization of the intestines by the vaccine carrier may result in 
gene/plasmid transfer to the host’s indigenous flora competitive exclusion of 
indigenous flora . 
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the biosynthesis of aromatic 
aminoacids or purines or cAMP, 
mutations affecting the global 
regulatory system phO/phQ have been 
used)   
Yersinia enterocolitica (Yop mutant, 
attenuated strain WA-314 sodA) 
 
Shigella spp. (induced mutation in 
virulent plasmid to generate non 
invasive, S. flexneri 2a. Istrati T32 is 
claimed be safer. Invasive-  Mutations 




Nasal administration of an attenuated 
strain of Bordetella pertussis (BPZE1) 
provided effective and sustained 
protection against lethal challenge with 










MHC class I and class II 
















An effective and sustained 
protection against lethal 
challenge with mouse-
adapted H3N2 or H1N1 
(A/PR/8/34) influenza A 
viruses 
Elicits strong cellular response. 
Useful in clearance of 
intracellular pathogens and 
cancer. Listeria based vaccine 
is under clinical trial phase I/II. 
 
Induce strong humoral and 
cellular immune response. 




Induce cellular immune 
response. Useful against viral 
diseases and cancer. 
 
 
Deliver DNA vaccine plasmids 
to mucosal sites and induce 




BPZE1 treatment protects mice 
from influenza virus-induced 
immunopathology and 
lymphocyte depletion. 
If virulence is not severely 
attenuated or if the mutated 
strain reverts to normal, 
listeria infection causes a 
fatal disease called 
listeriosis.  
Possibility for conversion 
from avirulent to virulent 




Poor colonizing ability in 
intestine and sometimes 
failure to elicit CD8+ T cell 
response in vivo. 
 
Possibility for conversion 
from avirulent to virulent 




The viral load is not 
significantly reduced in 
BPZE1-treated mice 
 
Jiang et al. 
2007, 





Bumann et al. 
2001, 
Medina et al. 
2001, 











Shata  et  al.  
2001. 
Vecino  et  al. 
2002, 







Li et al. 2010. 
Table 1.1. Attenuated pathogenic bacteria as vaccine vehicles 
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1.2.3. Commensal microorganisms as vaccine vehicles 
Different Lactobacillus spp. based vaccines have been developed and 
administered by the mucosal route, leading to the elicitation of both mucosal and 
systemic immune responses against the expressed antigens (Zegers et al. 1999; 
Gerritse et al. 1990). Lactococcus lactis (a non colonizing strain), Lactobacilli 
(which are able to colonize) and Streptococcus gordonii, (an oral commensal 
organism of human origin which has been known for its stable antigen 
presentation) are commonly used vaccine carriers. Recombinant S. gordonii has 
been employed to develop vaccines against sexually transmitted pathogens (Di 
Fabio et al. 1998).   
 
1.3. Lactic Acid Bacteria as vaccine vehicles  
Lactic acid bacteria (LAB) are a group of Gram positive non-sporulating bacteria 
that include species of Lactobacillus, Leuconostoc, Pediococcus and 
Streptococcus. LAB are attractive candidates for vaccine delivery vehicles 
because they are considered as GRAS (Generally regarded as safe) organisms 
with a very long record of safe oral consumption. They have the following 
advantages as vaccine delivery vehicles (Wells et al.  2008).  
1. LAB strains are able to effectively survive passage through the stomach. 
However the survival of LAB in stomach acid and contact with bile is strain 
dependent. 
2. The mucosal route of administration can stimulate systemic immune response 
and elicit mucosal immune response by the induction of secretory 
Immunoglobulin A. 
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3. When administered by the  oral route , LAB can be taken up into the PP, the 
major inductive site in the GI tract. 
4. Killed recombinant LAB can be used for intranasal immunization. 
5. LAB only induce a low-level immune response against themselves.   
6. Colonizing LAB can synthesize the antigen continuously at the desired 
mucosal surface thereby triggering the underlying immune system. 
 If LAB are used for immunization a high level of antigen synthesis will not be a 
prerequisite as they can colonise the gastrointestinal tract. In the case of 
colonizers, strains appropriate for human use have to be selected on the basis of 
safety.  Amongst LAB, the natural inhabitants of the gastrointestinal tract, 
Lactococcus lactis, Lactobacillus spp and colonizers of the oral cavity, 
Streptococcus gordonii are commonly used as vaccine carriers.  
 
Cytokine co-expression with antigen in LAB based vaccines 
Cytokine co-expression with antigen that delivered by LAB was believed to 
enhance the immune response than the antigen alone.   Intranasal immunization 
of lactococci expressing Tetanus Toxoid Fragment C (TTFC) with either IL-2 or 
IL-6 resulted in a more rapid response and higher endpoint titres of TTFC-
specific antibodies (Steidler et al, 1998). Co-administration of IL12 secreting L. 
lactis with a cell wall-anchored human papillomavirus type 16 E7 antigen 
elicited more antigen specific cellular immune response than E7 antigen 
expressing L. lactis administration alone (Bermudez-Humaran et al, 2003).  IL10 
secreting L. lactis was shown to alleviate the symptoms in Crohn’s disease and 
Irritable Bowel Disease (IBD) (Steidler et al, 2000). Co-administration of IL10 
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secreting L. lactis with allergen expressing L. lactis may be useful in asthma like 
allergic disorders (Frossard et al, 2007).  
 
1.3.1. Lactococcus lactis    
Unlike other LAB, Lactococcus lactis does not colonize the digestive tract of 
man or animals. In mice it persists in digestive tract for less than 24 hours and 
in humans it passes through the gut in 3 days (Mercenier et al. 2000).  As it has 
limited capacity to produce and secrete antigen in vivo, Lactococcus lactis has 
been engineered to express antigen intracellularly, so that the bacteria are pre-
loaded with antigen before they are used for immunization. Using the 
lactococcal T7 system, heterologous antigens have been expressed so that they 
make up about 2-20% of total cellular protein (Mercenier  et al. 2000).  The 
most complete immunological study has been conducted with recombinant 
Lactococcus lactis producing the Tetanus Toxin Fragment C (TTFC) 
(Robinson et al. 1997; Norton et al. 1995; Steidler et al. 2002).  Lactococcus 
lactis expressing TTFC on the membrane, intracellularly or as a secretory 
protein were administered without adjuvant to mice. All three Lactococcal 
TTFC expressor strains were able to elicit antibodies and protected the mice 
from lethal toxin challenge. Intranasal immunization of Lactococcus lactis that 
co-express TTFC with murine IL2 or IL6 demonstrated the advantage of 
cytokine co-administration with antigen in enhancing the humoral immune 
response (Steidler et al. 1998).  Its poor colonizing ability has been considered 
the main disadvantage of using Lactococcus lactis as a vaccine vehicle. 
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1.3.2. Streptococcus gordonii    
S. gordonii is one of the pioneer organisms in the oral cavity and likely to 
appear in the oral cavity as early as 6 months of age. The advantage of being a 
pioneer organism is that there is less competition from other organisms. The 
persistent nature of S. gordonii in the oral cavity suggests it can be a potential 
economical vaccine preferably to be used soon after birth (Lee et al. 2003). So 
far, there are two approaches that have been used to express heterologous 
proteins in S. gordonii.  One approach is to express the protein on the surface 
by exploiting the C-terminal surface anchoring domain of the M6 protein or P1 
antigen of Streptococus pyogens or Streptococcus mutans respectively.  In the 
second approach, secretion of the antigen into the culture medium is made 
possible by using the M6 protein or P1 antigen signal sequence. Oral 
immunization  with recombinant S. gordonii expressing tetanus toxin fragment 
C or Fim A has been shown to confer some protection against tetanus toxin 
lethal challenge in mice and prevent  alveolar bone loss induced by 
Porphyromonas gingivalis infection in rats respectively (Medaglini et al. 2001, 
Sharma et al. 2001). Antigens secreted or surface expressed by S. gordonii are 
immunogenic in mucosal as well as parenteral administration.  However, 
obtaining a high level of immune induction has been an obstacle in S. gordonii 
based vaccines.  
 
1.3.3. Lactobacilli   
Compared to Lactococci and S. gordonii, Lactobacilli have greater intrinsic 
immunogenicity and colonizing ability in the GI tract that make them 
potentially better candidates for vaccination. Lactobacillus plantarum, 
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Lactobacillus casei, Lactobacillus helveticus, Lactobacillus acidophilus, 
Lactobacillus reuteri, Lactobacillus brevis and Lactobacillus rhamnosus GG 
(LGG) are commonly used Lactobacilli for vaccine delivery (Table 1.2). 
Lactobacilli are non invasive and the vaccine delivery to antigen presenting 
cells may be less effective than with invasive bacteria. Still antigen specific 
immune responses have been obtained with Lactobacilli based vaccines.  
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Among Lactobacilli based vaccines, L. plantarum and L. casei are commonly 
used vaccine vehicles.  L. plantarum based TTFC vaccine delivery induced a 
higher TTFC specific antibody over L.casei in oral  and intranasal 
immunization of C57BL/6  and Balb/c mice. Mitomycin treated L. plantarum 
induced eight fold less neutralizing tetanus antibody levels than live bacteria 
though it elicted almost the same level of serum TTFC specific antibody in 
intranasal immunization. (Grangette et al. 2001). 
 L. plantarum has also been used to induce tolerance in treating allergy. 
Immunization of recombinant L. plantarum expressing house mite allergen Der 
p1 or mucosal co-application of  L. plantarum with birch pollen allergen Bet v1 
could suppress the dust mite specific T cell response or pollen allergen specific 
Th2 allergic immune response respectively (Kruisselbrink et al. 2001; Repa et 
al. 2003). Recombinant L. casei expressing transmissible gastroentritis 
coronavirus spike glycoprotein or Porcine Parvovirus VP2 protein elicited 
antigen specific mucosal IgA or serum antibodies by intragastic administration 
(Ho et al. 2005; Xu et al. 2007). Immunomodulatory potential of L. casei was 
demonstrated by showing significant inhibition of β-lactoglobulin specific IgE 
in oral immunization of BLG expressing L. casei (Hazebrouck et al. 2009). 
1.3.3.1. Lactobacillus rhamnosus GG  
Lactobacillus rhamnosus strain GG was discovered in 1985 (Gupta et al. 2009) 
and later, LGG  was sub grouped  as member of the L. casei based on cell wall 
peptidoglycans and the fermentation pathway of pentoses and hexoses 
(Hammes et al. 1995). LGG was the first probiotic, which received most 
clinical attention to date. (Gorbach et al. 2000). The health promoting effects 
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of LGG have also been studied extensively, making it the best characterized 
probiotic bacterium. 
 
1.3.3.2. Benefits of using LGG 
1.  Survival of LGG in the human gastrointestinal tract -  In human trials, LGG 
was shown to survive better in the gastrointestinal tract and to persist in 87% or 
33% (sample size - 77) of volunteers for 4 or 7 days after oral consumption of 
bacteria. (Goldin et al. 1992) 
2.  Better adherence   to  mucosal tissue -  LGG was demonstrated to have a 
strong  
in-vitro adherence to HT-29 cells (Verdenelli et al. 2009). The strong adherent 
ability of LGG to cervico-vaginal cells and antagonistic effect on vaginosis 
associated pathogens also   have been reported (Coudeyras et al. 2008). 
3. Easing symptoms of gastrointestinal disorders. A clinical study done by The 
European society for Pediatric Gastroenterology, hepatology, and nutrition  
involving 287 children aged 1 - 36 months from 10 countries suffering from 
moderate to severe diarrhoea showed that patients receiving LGG had 
decreased severity and shorter duration of illness. (Guandalini et al. 2000). 
LGG was reported to block inflammatory signaling in vivo via reactive oxygen 
species generation and thereby may prevent necrotizing enterocolitis (NEC) in 
premature infants ( Lin et al. 2009).  
4. In alleviating allergic reactions- The immunomodulatory potential of LGG 
in allergic conditions has been extensively documented. LGG consumption in 
pregnant women for 2 - 4 weeks before their delivery date reduced the 
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incidence of atopic eczema in their children who were breast fed. (Kalliomaki 
et al. 2001). 
5. In cancer - LGG cytoplasmic fraction exerted  antiproliferative and 
proapoptotic effects on HGC-27 human gastric carcinoma cell lines. (Russo et 
al. 2007). LGG was also reported to induce antiproliferative or cytotoxic 
effects on human transitional carcinoma cell lines MGH and RT112 
respectively. (Seow et al. 2002).  LGG DNA containing novel 
oligodeoxynucleotide pattern elicited a strong immunostimulation in murine 
immune cells ( Iliev et al, 2005). In  mice bearing bladder tumours oral 
administration of LGG immediately after tumor cell implantation reduced the 
tumour size and inhibited tumour development. (Lim et al. 2002) 
 
Lactobacillus rhamnosus GG as vaccine vehicle  
Despite of having many beneficial effects on consumption, LGG has been 
poorly exploited as a vaccine delivery vehicle.  
 
1.3.4. Dose and route of administration of lactobacilli:  
Many studies were  performed to analyze the effective dose of lactobacillus 
that could  induce an immune response and enhanced phagocytic cell function  
which has been taken as an index of immune enhancement by lactobacillus 
(Perdigon et al. 1986). Generally oral delivery of 109 cfu (LGG HN001) was 
found to be effective in enhancing an immune response (Gill et al. 2000). A 
dose of 107cfu LGG HN001 was also shown to be sufficient to enhance the 
phagocytic capacity of blood leukocytes but a minimum daily dose of 109 cfu 
was found necessary to enhance the phagocytic capacity of peritoneal cells 
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(Gill et al. 2001). Interestingly, there was no further increase in peritoneal cell 
phagocytosis by increasing the dose from 109 to 1011 cfu.  However the 
effective dose of recombinant lactobacilli may vary depending on the 
immunogenicity and stability of the heterologous protein. 
In mucosal delivery the choice of the immunization route may be crucial in 
inducing an effective immune response. Sometimes antibody induction may 
vary based on the route of immunization. For example, intranasal delivery of β- 
lactoglobulin (BLG) producing L. casei stimulated serum BLG-specific IgG2a 
and IgG1 responses and fecal IgA response as well, but did not inhibit BLG 
specific IgE induction. However intranasal immunization of recombinant 
lactobacilli expressing IgE mimotope induced anti IgE pecific IgG response 
which may be a clinical benefit for atopic patients (Scheppler et al, 2005).  In 
contrast oral immunization of the same bacteria inhibited BLG specific IgE 
production while IgG2a and IgG1 responses were not stimulated (Hazebrouck 
et al. 2009). There have been controversial reports on the efficacy of the 
immune response with regard to the route of immunization either oral or 
intranasal using LAB as the vaccine (Cheun et al. 2004; Ramasamy et al. 2006; 
Oliveira et al. 2006; Robinson et al. 1997). Bacteria strain, booster 
immunization, choice of antigen expression (cytoplasmic, secreted or cell wall 
anchored) and scheme of immunization may determine the efficacy of 
immunization via different routes.  
Another important factor, bacterial persistence or colonization at mucosal sites 
should be considered. For instance, the efficacy of intranasal immunization of 
lactobacilli was greater compared to Lactococcus lactis and the difference in 
immune induction was explained by low level of antigen expression in 
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Lactococcus lactis or the fact that lactobacilli were able to persist in mice nasal 
mucosa for up to 3 days while Lactococcus lactis were detectable only after the 
first day of inoculation (Oliveira et al. 2006). 
 
1.3.5. Immunomodulatory functions of lactobacilli on dendritic cells and 
neutrophils: 
Dendritic cells (DC) play a pivotal immunoregulatory role in the Th1, Th2, and 
Th3 cell balance and are present throughout the gastrointestinal tract. Thus, DC 
may be targets for modulation by gut microbes, including ingested probiotics. 
The different species of Lactobacillus differentially activate DC. When bone 
marrow-derived murine DC were exposed to various lethally irradiated 
Lactobacillus spp, almost all different strains up-regulated surface MHC class 
II and B7-2 (CD86), though  they induced diffrential cytokine production from 
DC. Significant differences among the lactobacilli species were observed for 
the production of IL-12 and TNF-α   with the following ranking of the species 
L. casei >> L. plantarum Lb1 > L. fermentum ∼L. johnsonii ∼L. plantarum  
>> L. reuteri (Christensen et al, 2002). Lactobacilli activated human dendritic 
cells skew T cells toward T helper 1 polarization. Lactobacilli treated 
monocyte derived human dendritic cells co-cultured with  T cells induced 
allogeneic or autologous CD4+ and CD8+ T cell proliferation  (Mohamadzadeh 
et al, 2005) .   
Recently more interest has been shown on the role of neutrophils in antigen 
presentation. Neutrophils may influence T cell responses to bacteria, either by 
directly presenting peptide-MHC-I complexes or by delivering peptides to 
other APCs for presentation (Potter et al, 2001). Neutrophils were recently 
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shown to be able to cross present antigens to cytotoxic T cells.   Cross-
presentation by neutrophils was TAP and proteasome dependent and was as 
efficient as in macrophages. Moreover, it actually occurred earlier than in 
professional antigen-presenting cells. 
However only limited literature is available on lactobacilli mediated direct 
immunomodulatory effect on neutrophils. In vitro experiments with 
Lactobacillus plantarum showed an inhibited intestinal epithelial migration of 
neutrophils induced by enteropathogenic Escherichia coli (Michail et al, 2003). 
Primary culture of peritoneal neutrophils treated with L. casei lysates showed  
higher Nitric Oxide  production and demonstrated an enhanced phagocytotic 
and free radical scavenging activity (Lee et al, 2010). Lactobacillus casei 
treatment restored neutrophil phagocytic capacity in cirrhosis, possibly by 
changing IL10 secretion and TLR4 expression (Stadlbauer  et al, 2008). 
However lactobacilli mediated indirect DC activation by neutrophils has not 
been evaluated. 
  
1.4. Role of promoter and cellular location (surface/intracellular/cell wall 
anchoring/ secretory) of antigen in immune induction 
Studies of gene expression and regulation in lactobacilli have received more 
attention recently for their potential role in heterologous expression of protein 
especially industrially important enzymes. Constitutive and inducible promoter 
systems in lactobacilli have been well exploited to express foreign proteins. A 
constitutive promoter system is a natural choice for colonizing lactobacilli 
during in situ production in the human body or when steady state gene 
expression is required (Jensen et al. 1993). Efficient and established 
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constitutive promoters used in lactobacilli were lactate hydrogenase (ldh) and 
surface layer protein A (slpA) promoters (Table 1.3). In constitutive 
expression, continuous high-level of production of a protein could lead to 
intracellular accumulation, aggregation, or degradation of protein in the 
cytoplasm which is deleterious to cells (Makrides et al. 1996). In that case, 
inducible expression would be the best choice.  Inducible expression may also 
be preferable in cases where the aim is to overproduce a desired protein at high 
levels. For inducible promoters, several expression systems have been 
constructed for Lactococcus lactis (Sorvig et al. 2003, 2005). Among the 
inducible promoters, the bacteriocin inducible system is one of the most 
commonly used (Table 1.4). Many LAB produce antimicrobial peptides called 
bacteriocins and their production is regulated by the secreted peptide 
pheromone which activates a two component regulatory system consisting of a 
histidine kinase receptor and cognate response regulator. In strains, producing 
class I bacteriocins (such as nisin), the bacteriocin itself acts as pheromone 
(Kuipers et al. 1995). Strains producing class II bacteriocins, such as sakacin A 
and sakacin P produce a separate peptide pheromone (Nes et al.1999). In both 
cases, pheromones activate the transcription of all the operons involved in 
bacteriocin production through the response regulator. Though the best 
characterized and most commonly used controllable expression system is the 
nisin controlled expression (NICE) system, in which nisin serves as an inducer,  
(de Ruyter et al. 1996a; de Ruyter et al.  1996b) it often exhibits significant 
basal activity, i.e. activity without activation. (Eichenbaum et al. 1998; Pavan 
et al. 2000). In that case inducible expression system involving class II 
bacteriocins may be preferred. 
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Promoter Source Host for expression Cellular location of 
the antigen 
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Table 1.3.  Heterologous protein expression under constitutive promoters in LAB 
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Table 1.4.  Heterologous protein expression under Inducible  promoter in LAB 
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1.5. Mucosal vaccine- challenges 
In recent years, the use of recombinant LAB for mucosal delivery has been given 
more attention. Despite much progress, there are several issues that still need to be 
addressed.  
1. LAB vaccines that are administered orally or intranasally get diluted in mucosal 
secretion and trapped in mucus gel. Relatively larger doses of vaccine may be 
required and it is hard to determine what dose actually crosses the mucosal layer. 
2. The most frequently asked question about the LAB based mucosal vaccine is the 
possible induction of mucosal tolerance. Repeated oral ingestion of antigen results 
in decreased or totally abrogated responsiveness to subsequent systemic 
immunization with the same antigen. Though some LAB are intrinsically 
immunogenic, additional adjuvants like cholera toxin (CT) or cytokine co-
expression may help to avoid tolerance induction.  
3. Recombinant bacterial vaccines when administered induce immune responses 
against the vaccine antigen initially, but the response to the neo-antigen is 
overwhelmed by response to the more immunodominant antigen of the bacteria 
itself.   
4.  The effectiveness of the live bacterial vaccines is partly dependant on the 
transport to organised lymphoid tissues. Vaccines derived from pathogenic 
microbes like live attenuated S. typhi (Levine et al. 2000) or live attenuated polio 
virus (Modlin et al. 2004) preferentially adhere to M cells and exploit M-cell 
transport to invade organized mucosal lymphoid tissues in the intestines (Jones et 
al. 1994; Sicinski et al. 1990). Lactobacilli are not known to invade lymphoid 
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tissue as the microbes discussed above. However expressing foreign protein with 
DC targeting peptide may improve  bacterial uptake (Mohamadzadeh et al. 2009). 
   
1.6. Scope of study 
To date, there is limited literature documenting the use of LGG as a vaccine 
vehicle.  Our hypothesis is  
 LGG can be a good antigen delivery vehicle in mucosal immunization and this 
dissertation aims to characterize LGG as vaccine delivery vehicle in the following 
manner. 
Objectives of the work  
a)  Study the humoral and cellular immune response by oral or nasal immunization 
in mice using GFP (Green Fluorescent Protein) as a model antigen expressed in 
LGG.  
b) Study the advantage of Interleukin-2 (IL2) co-expression with antigen in 
enhancing specific immune induction  
   c) Study the dendritic cells and neutrophils mediated antigen presentation of IL15 
or IL2 or IL7- Prostate Specific Antigen (PSA) fusion protein secreting LGG to 
activate T cells. 
d)  Study the compatibility of different promoters in LGG and optimization of the    




                                                                                                                                    
                                          
31
 
      
      
     
     Chapter Two 
        Materials 
            and  









                                                                                                                                    
                                          
32
 
2. Materials and methods 
 
2.1 Production of Lactobacillus rhamnosus GG expressing protein antigens  
 
2.1.1 Lactobacillus rhamnosus strain GG (LGG) 
Lactobacillus rhamnosus GG  (ATCC 53013) (a kind gift from Dr Seppo 
Salminen of University of Turku, Finland) growth curves  were produced by 
plotting OD550 nm versus number of bacterial colonies of freshly prepared, 
serially-diluted cultures grown on de Man, Rogosa, Sharpe (MRS) (Merck, 
Darmstadt, Germany) agar plates. Bacteria were harvested at the late log phase 
(OD550 nm for L. rhamnosus  was 5.2) 
and the CFU were approximately 3 x 109 colony forming units/ml (cfu/ml). 
Overnight cultures of LGG were routinely used for animal experiments. The 
bacteria were grown and maintained in MRS media (Merck) at 37oC. To avoid 
strain variation from prolonged culture, new LGG glycerol stocks were thawed to 
start a fresh culture every 2 - 3 months. 
2.1.2. Plasmid for protein expression in Lactobacillus. 
 
 p 
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Figure 2.1. Restriction map of E. coli- Lactobacillus shuttle vector, pLP500 
 The Lactobacillus - E. coli shuttle vector pLP500 (Fig 2.1), was obtained from 
Prof. Pouwels PH of the TNO-Nutrition and Food Research Institute, The 
Netherlands. The plasmid contains the constitutive promoter of the L-(+)-lactate 
dehydrogenase  
(L-ldh) gene, downstream of the secretory signal of the prt P gene of L. casei 
which confers secretable expression (Ho et al. 2005) It also carries both ampicillin 
and erythromycin resistance genes for selection in E.coli or Lactobacilli 
respectively.  
 
2.1.3. LGG-green fluorescent protein (LGG-GFP)  
LGG-eGFP (enhanced Green Fluorescent Protein) was a gift from Prof. Chua Kaw 
Yan, Dept of Pediatrics, National University of Singapore, Singapore. LGG-GFP 
was cultured in MRS media supplemented with 10 g/ml erythromycin (Sigma-
Aldrich, St. Louis, MO) 
 
2.1.4. Cloning of murine Interleukin-2 (IL2) gene to generate IL2-GFP fusion 
protein 
The mature peptide sequence (nucleotides 108 - 554bp) encoding mouse 
interleukin-2 was amplified from pBUD-IL2 plasmid by polymerase chain 
reaction using the primers listed in Table. 2.1(a). The 3’ primer  was designed 
without its termination codon and after subcloning into the pLP500 vector at the N 
terminus of the GFP gene, 2 amino acids, glycine and serine were inserted before 
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the GFP protein sequence. The construct pLP500-IL2-GFP was verified by 
nucleotide sequencing. 
 
2.1.5. Genomic DNA extraction from L. acidophilus 
Genomic DNA from L. acidophilus was extracted as described before (Martin-
Platero et al. 2007) with some modifications. An overnight culture (50-100ml) of 
L. acidophilus was centrifuged and resuspended in 100 ml TES buffer (10% 
sucrose, 25 mM Tris HCl pH 8.0, 10 mM EDTA). Then 10 mg/ml of freshly 
prepared lysozyme, 100 U/ml mutanolysin and 40 µg/ml of RNase were added and 
incubated for 30 minutes at 37°C. Cells were pelleted down and lysed with 600 µl 
of lysis buffer (100 mM Tris HCl pH8.0, 100 mM EDTA, 10 mM NaCl and 1% 
SDS) by mixing gently and incubated for 10 to 15 minutes at room temperature. 
The lysate was treated with proteinase K (10 mg/ml) and incubated for 15 minutes 
at 37°C followed by another incubation at 80°C for 5 minutes. Then samples were 
allowed to cool to room temperature for 10 minutes. 200 µl of 3M sodium acetate 
pH 5.2 was added and the sample was vortexed for 10 - 15 seconds and chilled for 
10 - 15 minutes. Then the sample was centrifuged at 20,000x g for 10 minutes to 
precipitate proteins. The supernatant was transferred to a new tube and DNA was 
precipitated by adding an equal volume of isopropanol. The tube was inverted 
several times and DNA was precipitated by centrifugation at 20,000x g for 5 
minutes. The pellet was washed once with 1 ml 70% ethanol and subsequently 
dried at room temperature. Finally the DNA was resuspended in 200 µl of TE 
buffer and analyzed  by gel electrophoresis. 
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2.1.6. Replacement of the ldh promoter of pLP500 with the slpA promoter to 
produce pLP500-slpAP plasmid 
 The slpA (S-layer protein gene) promoter with secretory signal peptide sequence 
was amplified by PCR using the primer pair listed in Table 2.1(a) which were 
designed to have a BglII site at the 5’end and EcoRV site at the 3’end respectively.  
This amplified PCR product replaced the Pldh promoter in pLP500 by restriction 
digestion with BglII and EcoRV and the plasmid produced was named pLP500-
slpAp.  
 
2.1.7. Producing different promoter constructs to modify antigen secretion  
The core ldh promoter without ribosome binding site (RBS) or coding sequence 
was amplified by PCR from genomic DNA of L. casei using the primer pair listed 
in Table 2.1 (b) which were designed to have a BglII site at both 5’ and 3’ends and 
subcloned  in to pLP500-slpAp plasmid, upstream to slpA promoter sequence. The 
construction and orientation of the Pldh  insert was confirmed by sequencing.   
The putative promoter of L. acidophilus  pgm gene was amplified from genomic 
DNA by PCR using the primer pair listed in Table 2.1(b) which were designed to 
have a Bgl II site at the 5’ end and EcoRV at 3’ end and subcloned into BglII, 
EcoRV digested pLP500 plasmid to produce pLP500-pgmp plasmid. The 
construction was confirmed by sequencing. 
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2.1.8. Cloning of murine IL2 in pLP500ldh-slpAp (tandem promoter) or 
pLP500-pgmP plasmid  
Mouse interleukin-2 was amplified from pBUD-IL2 plasmid as described above 
and subcloned in to pLP500ldh-slpAp or pLP500-pgmp and or pLP500.  The 
constructs were verified by nucleotide sequencing. 
 
 2.1.9. Cloning of human Prostate Specific Antigen (PSA) or murine IL2 or 
IL15 or IL7 in pLP500-slpAP plasmid. 
A 0.69 kbp cDNA fragment (nucleotides 136 - 827), encoding PSA or kallikrein-
related peptidase 3 (KLK3) gene was amplified from pSec Tag2/Hygro/PSA 
plasmid (Invitrogen, CA, USA) by PCR using the primers listed in table 2.1(a) and 
subcloned into pLP500 plasmid, downstream to the slpA promoter sequence. The 
construction of the gene and whether the psa gene was in frame with slpA signal 
peptide sequence were confirmed by sequencing. For mouse IL2, IL15 and IL7 the 
primers listed in Table 2.1(a) were used to amplify the mature pepetide sequence 
of the respective cytokines which were cloned singly and upstream of PSA.  
                                                                                                                                    


















Primers  Plasmid produced/ 
recombinant LGG 
Genomic DNA of  
L. acidophilus  
 
Nucleotide -286 to + 111 of the slp promoter region with secretion signal 
forward primer  5' GGG AGA TCT TGC TTG TGG GGT AAG CGG TAG 3’ and   
Reverse primer  5' GAT ATC TGC GTT AAT AGT AGT AGC AGC GC '3 




pSec Tag2/Hygro/PSA nucleotide 136-827 of PSA  gene (codes for mature protein minus 8aa) 
forward primer  5'  CC GAT ATC ATG GAG AAG CAT TCC CAA CCC 3’ and   
Reverse primers  5’GGG GAT CC TCA GGG GTT GGC CAC GAT GGT 3’  
which contained EcoRV and BamH1 
pLP500slpAp PSA/ 
LGG-S-PSA 
mature peptide nucleotide sequence 108-554bp 
Forward primer  5’ GGG GAT CC GCA CCC ACT TCA AGC TCC AC 3’ and 
Reverse primer  5’GAT GGG GAT CC TTG AGG GCT TGT TGA GAT 
which contained BamH1 at both sites 
mature peptide nucleotide sequence 108-554bp 
Forward primer  5’CC GAT ATC GCA CCC ACT TCA AGC TCC AC 3’ and  
Reverse primer  5’GAT GGG GAT CC TTG AGG GCT TGT TGA GAT 3’  
which contained EcoRV and BamH1 
pLP500ldhp IL2- GFP 
LGG-IL2-GFP 
 




Reverse primer  5’ GAT GGG GAT CC T TAT TGA GGG CTT GTT GA3’ pLP500slpAp IL2/ 
 LGG-S-IL2 
Mature peptide encoded by nucleotides 610-951bp 
Forward primer  5’CC GAT ATC AAC TGG ATA GAT GTA AGA TAT G 3’ and  
Reverse primer  5’ GGG GAT CC GGA CGT GTT GAT GAA CAT 3’ 






Reverse primer  5’ GGG GAT CCT CAG GAC GTG TTG ATG AAC AT3’ pLP500slpAp IL15/  
LGG-S-IL15 
Mouse IL7 mRNA encoded by nucleotides 247-712 bp  
Forward primer   5' GG GAT ATC ATG TTC CAT GTT TCT TTT AGA  3'  and  
Reverse primer   5’ GGG GGA TCC TAT ACT GCC CTT CAA AAT TTT  3’ 




Mouse bone marrow cells 
Reverse primer   5’ GGG GGA TCC TTA TAT ACT GCC CTT CAA AAT TTT   pLP500slpAp IL7/ 
 LGG-S- IL7 
Table 2.1 (a). Plasmids  generated 
                                                                                                                                    




2.1.10. Preparation of LGG electrocompetent cells 
Preparation of electrocompetent LGG was done as described before (De 
Keersmaecker et al. 2006) with some modifications. An overnight culture of LGG 
was inoculated into prewarmed MRS medium supplemented with 2% glycine and 
was incubated without agitation at 37°C. After overnight growth, 5ml of the 
culture in the exponential growth phase (OD 600 0.8 to 1) was inoculated into 100 
ml of prewarmed MRS medium supplemented with 2% glycine. The resulting 
culture was kept in a tightly closed 100ml flask and incubated without agitation at 
37°C. When the OD 600 was 0.2 to 0.3, ampicillin (10 μg/ml) was added and 
bacteria were further incubated to an OD 600 reading of 0.4 to 0.5. Cells were 
harvested by centrifugation at room temperature for 10 minutes at 4000x g. The 
cells were washed three times with electroporation buffer (0.4 M sucrose, 5 mM 
potassium dihydrogen phosphate [pH 6.0], 1 mM MgCl2) at room temperature and 
finally resuspended in 1 ml of the same buffer and placed on ice. The 
Plasmid/DNA 
source 










Genomic DNA of  
L. acidophilus 
 
Nucleotide  -511  to  -18 of the ldh promoter region  
Forward primer   
5' GGG AGA TCT GAA TTC AGA TCT ACT AGA 
GGA TCT GTG 3’ 
Reverse primer  
5’ CCC AGA TCT TTA TGT GCA TGC AAA CTG C 3’. 
which contained Bgl II at both sites. 
 
putative promoter region of pgm gene. 
Forward primer  5' GGG AGA TCT TGC GAC AAG TAA 
TAA ACT AAA C 3’ 
Reverse primer 5’ CCC GAT ATC AGC CTT CTT AGC 
TTC TTC AAC A 3’ 
which contained Bgl II and EcoRV sites. 
 
 







Table 2.1 (b). Plasmids  generated 
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electrocompetent cells were used immediately for electroporation.  
 
2.1.11. Electroporation of LGG. 
Electroporation was performed as described before (De Keersmaecker et al. 2006). 
A mixture containing 100 µl of a cooled cell suspension and 400 ng of plasmid 
DNA  
(maximum volume 5 µl) was transferred into a precooled electroporation cuvette 
(Bio-rad, CA, USA)  with a  0.2 cm electrode gap and immediately electroporated 
(Gene Pulser: Bio-rad) using the following settings; peak voltage, 1.7 kV:; 
capacitance, 25 µF: and parallel resistance, 200Ω. Following the pulse, the cells 
were immediately diluted with 5 ml of MRS medium containing 2mM CaCl2 and 
20mM MgCl2 and incubated for 37°C for 3 hours without agitation before they 
were plated onto MRS agar plates containing the 10 µg/ml of erythromycin. Plates 
were incubated at 37° C, 5% CO2 for 48 to 72 hours. 
 
  2.1.12. Determination of IL-2 or IL-15 biological activity 
The IL2 dependent mouse cytotoxic T lymphocyte cell line – CTLL-2 (ATCC, 
Manassas,VA,USA) ( ATCC number- TIB-214™ ) was purchased from ATCC 
and maintained in RPMI 1640 media (Sigma Aldrich) supplemented with 2 mM L-
glutamine (Sigma Aldrich), 1 mM sodium pyruvate (GIBCO BRL, CA, USA), 
10% v/v foetal bovine serum (FBS) (Hyclone, USA) and 5000U/ml Penicillin and 
5 mg/ml Streptomycin (Sigma Aldrich) and 10% T-STIM with Con A ( BD 
Biosciences, San Jose, CA, USA) . For the proliferation assay, the cells were 
                                                                                                                                    
                                          
40
washed twice and suspended at 1.4 x 105 cells per ml in IL-2 free media (T-STIM 
with Con A) as described by Vorauer et al. 1996. Recombinant human IL-2 (e-
bioscience, San Diego, CA,USA.) from 20 to 0.3 U/ml or conditioned media, that 
was prepared from bacterial supernatant (from LGG-IL2 [ldhp]  or LGG-IL2-GFP 
or LGG-IL2[SlpAP] or LGG-IL15 or LGG-IL2-PSA or LGG-IL15-PSA) dialyzed 
against blank RPMI media were added to the cells for 28 - 72 hours. Cell 
proliferation was determined by CellTiter 96® AQueous Non-Radioactive Cell 
Proliferation Assay (MTS) (Promega, Madison, WI, USA). 
 
2.1.13. Analysis of cytokines, PSA or GFP  expression  
GFP expression in the bacteria was analyzed on a Coulter EPICS ELITE ESP flow 
cytometer. GFP in LGG-GFP or LGG-IL2-GFP culture supernatant or bacteria 
lysates were determined by ELISA (Reacti-Bind Anti GFP coated plates, Pierce 
biotechnology Inc, Rockford, IL, USA) and GFP fluorescence was detected by a 
luminescence spectrometer (Perkin-Elmer LS50B, Waltham, Massachusetts, USA) 
(De Keersmaecker  et al. 2006).  
Recombinant LGG were initially inoculated in 5ml of MRS broth with 10 μg/ml of 
erythromycin (Sigma Aldrich) and incubated at 37ºC for 8 hours. Then the culture 
was diluted 20 times with MRS broth containing 10 μg/ml of erythromycin and 
incubated up to 20 - 22 hours when the culture supernatants were harvested and 
analyzed for cytokine or PSA. IL2 (BD Biosciences), IL15 (eBiosciences) and IL7 
(Ray biotech, Norcross GA, USA) were analyzed with commercial ELISA kits. 
For ELISA, briefly, 100 l capture antibody (Ab) diluted in coating buffer was 
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added to each well, and incubated overnight (4oC) except for IL7 in which 
precoated plates were used. The plates were then washed three times with wash 
buffer (PBS with 0.05% v/v Tween 20) and blocked with 200 l assay diluent ( 
RT for 1 hour). Following which, the plates were washed 3 times before the 
addition of 100 l standard or bacterial supernatant from LGG (neat or diluted). 
Plates were incubated for 2 hour at RT. The plates were washed again, then 100 l 
working detector (biotinylated detection Ab and streptavidin-horseradish 
peroxidase conjugate [HRP]) was added to each well (RT, 1hour). The plates were 
then washed before 100 l TMB substrate solution (Pierce Biotechnology Inc) was 
added to each well, and incubated in the dark (RT, 30 min). The reaction was 
stopped with the addition of 50 l stop solution (2N H2SO4) to each well. The 
absorbance was read at 450 nm; reference wavelength 570 nm (Tecan GENios/ 
Magellan, Männedorf, Switzerland). For PSA ELISA, MaxiSorp™ immuno 
modules (NUNC, Roskilde, Denmark) were coated overnight at 4oC with 1 μg/ml 
rabbit anti human PSA antibody (US Biologicals, Swampscott, MA) in 1x Tris 
Buffered Saline (TBS – 50 mM Tris, 150 mM NaCl, pH adjusted with HCl to 7.4). 
Then the plates were washed once with washing buffer (TBS containing 0.1% 
Tween 20) and blocked with 300 μL of TBS containing 2% BSA for 3 hours at RT 
with gentle shaking. Subsequently the plates were washed 3 times before either 50 
μL of PSA  standards (Chemicon, Temecula, CA) and dialyzed bacterial 
supernatant (neat or diluted in TBS containing 0.05% BSA) were incubated for 1 
hour at RT with gentle shaking. The plates were washed 5 times with the washing 
buffer before adding 100 μL of the secondary antibody (1 μg/mL mouse anti-PSA 
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monoclonal antibody conjugated with horseradish peroxidase, US Biologicals, 
Swampscott, MA) diluted in 0.5% BSA and 0.1% Tween 20 in TBS. After 1 hour 
at RT with gentle shaking, the plates were washed 5 times with the washing buffer. 
The plate was then developed using 1-Step™ Turbo TMB-ELISA substrate 
(Pierce Chemical Co.) for 30 minutes at RT in the dark. The reaction was stopped 
by adding 2N H2SO4 and the absorbance was read at 450 nm; reference 
wavelength 570 nm.  The Cytokine or PSA concentration read off the appropriate 
standard curve. Cytokines or PSA secretion were expressed as ng/ml of 
supernatant.  
 
2.2 In vivo analysis of LGG vaccines  
2.2.1. Animals  
4 – 6 week old female C57BL/6 mice were maintained at the National University 
of Singapore’s (NUS) Animal Holding Unit throughout the duration of the 
experiment with food and water ad libitum. The mice were acclimatized for a 
week prior to the start of each experiment. All experiments were performed 
according to guidelines set by the NUS Institutional Animal Care and Use 
Committee (IACUC).  
 
2.2.2. Translocation of bacteria 
Four groups (n=12/group) of mice were immunized via the nasal or oral route with 
“live” 108  LGG-GFP or LGG-IL2-GFP, or with sterile PBS. Four mice from each 
group were euthanized after 24h, 48h and 1 week. NALT, cervical lymph node 
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(CLN) and mediastinal lymph Nodes (Med.LN) or Mesentric lymphnodes  were 
harvested in intranasally or orally immunized mice respectively. Spleen and liver 
tissues were also collected and the tissues were homogenized in an ice bath using 
polytron homogenizer equipped with metal probe. The homogenates were serially 
diluted with sterile saline and plated on MRS agar plates containing 10 µg/ml 
erythromycin. Bacterial colonies were enumerated after 48 – 72 hours and data 
was expressed as CFU per gm of tissue.  
 
2.2.3. Intranasal immunization protocol and immune cells, cytokine analysis 
in BAL    (Bronchoalveolar lavage)  fluid 
For intranasal immunization, four groups with twenty mice each were immunized 
under anesthesia with either 108 LGG or LGG-GFP or LGG-IL2-GFP or with PBS 
(20 µl) on days 0, 14 and 28 as previously described (Steidler et al. 1998). Four 
mice from each group were euthanized on days 0, 10, 24, 35 and 80 and the serum 
and BAL fluid were collected (Hopfenspirger et al. 2002) and centrifuged to 
separate the cells from the fluid. The BAL supernatant was stored in aliquots at -
80ºC for cytokine analysis. The cells were H & E stained and enumerated.  
NALT and CLN were harvested on the 10th, 24th and 35th days and single cell 
suspensions were prepared for flow cytometry. Collected NALT tissues were 
mashed and single cell suspension was prepared by filtering through a 70 µm cell 
strainer (BD Falcon, USA). CLN tissues were placed in a 6-well culture plate on 
ice and cut into fine pieces. Subsequently they were digested with collagenase 
(Sigma Aldrich) resuspended in complete media (1 mg/ml per tissue) for 30min at 
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37oC with shaking. The suspension was then filtered through a 70 m cell strainer 
(BD Falcon, USA) and collected in a 2 ml tube, then centrifuged at 8,000 rpm 
(4oC, 2 min). The supernatant was removed and the pellet subjected to red blood 
cell (RBC) lysis using RBC lysis buffer (150 mM NH4Cl, 10 mM KHCO3, 0.1 
mM EDTA). The lysed suspension was then centrifuged at 8,000 rpm (4oC, 2 min) 
(Eppendorf Centrifuge, Hamburg, Germany) and the cell pellet was rinsed twice 
with cold PBS. The cells were finally resuspended 1 ml PBS with 0.01% sodium 
azide, 1% (w/v) bovine serum albumin (BSA) and 0.1% formaldehyde for flow 
cytometry analysis. Single cell suspensions from the CLN were stained with 
antibodies to B220, IgA, CD4, CD8, CD3, Mac-3 (M3/84) and pan NK(DX5) (BD 
Pharmingen, USA) while those from the NALT were stained with B-220 and IgA 
antibodies. About 1.0 x 104 cells were examined on a Coulter flow cytometer 
(Fullerton, CA, USA) and analyzed with Win MDI software.  
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Table 2.2. Primer sequences for Reverse transcriptase polymerase chain reaction  
(RT-PCR) 
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2.2.4. Expression of inflammatory cytokines and receptors in mice lung after 
35th or 80th day of post primary intranasal immunization     
Mice lungs were harvested on the 35th or 80th day of post primary nasal 
immunization and one  lung from each treatment group was used to probe a mouse 
inflammatory cytokines and receptors Oligo GEArray (SuperArray, USA) 
according to manufacturer’s instructions. Briefly, total RNA was extracted using 
Trizol (Invitrogen Life Technologies, Inc.) and poly A+ RNA was isolated using 
Oligotex mRNA Kit (Qiagen, Germany). Biotinylated cRNA was synthesised 
from the purified poly A+ RNA using the TrueLabeling-AMP Linear RNA 
Amplication Kit (SuperArray, USA). The target cRNA probe (5 g) was allowed 
to hybridize to the membrane for 24 hours. The chemiluminescent array image 
was recorded on X-ray film and the scanned TIFF image of the array was then 
analyzed with the GEArray Expression Analysis Suite. 
 
2.2.5. Reverse transcriptase polymerase chain reaction (RT-PCR) 
To corroborate the oligo array data, lungs from immunizaed mice on 35th or 80th 
day of post primary immunization were harvested. Total RNA (1 g) was used to 
generate cDNAs with 80 units M-MuLV Reverse Transcriptase (New England 
Biolabs, USA) with specific primers sets (Table 2.2) for amplification of GAPDH, 
chemokine (C-C motif) ligand 2, Ccl6, Ccl17 and Ccl25 Chemokine (C-X-C 
motif) ligand 5, chemokine (C-C motif) receptor 2 and Fc gamma receptor 1 (Fc 
r1).  
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For IL1rl,, IL10, IL16, IL2rg, IL5ra and IL20, 5 g total RNA and 80 units of 
Superscript II RNase H- Reverse Transcriptase (Invitrogen Life Technologies, Inc.) 
were used. Specific primer sequences are listed in Table 2.2. 
The PCR assay conditions for the housekeeping gene, Rps27a were: 94°C for 5 
min, 30 cycles of amplification (94°C for 45 sec, 55°C for 45 sec [annealing 
temperature], 72°C for 60 sec), and an additional extension step of 72°C for 5 min. 
Primer sequences for all other genes are also listed in Table 2.2 along with their 
respective annealing temperature. PCR products were separated on a 1.5% agarose 
gel containing ethidium bromide and then photographed under ultraviolet light. 
The message band intensities were quantified with SynGene GeneTools analysis 
software. The values of the mRNA transcripts were normalized against Rps27a. 
 
2.2.6. Histopathological analysis of the immunized mice lungs 
Lung tissues were harvested on the 35th and 80th days, fixed with 10% phosphate-
buffered formalin and embedded in paraffin for sectioning. Sections   4m thick 
were cut and stained with hematoxylin and eosin (H & E) reagent to evaluate the 
general morphology. The specimens were examined by Dr. Nilesh Shah, 
pathologist, Dept of Pathology, NUS  who was blinded to the treatment groups. 
 
2.2.7. Immunohistochemical staining 
Lung tissues were harvested on the 80th day and snap frozen in isopentane (Sigma 
Aldrich) prechilled in liquid nitrogen and stored at -80ºC. 10 μm Cryosections 
(Leica microsystem GmbH) were air-dried on poly-L-lysine coated glass slides. 
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They were overlaid and incubated for 1 hour at RT with 5% normal goat serum 
(Dako).  
B cells or IgA were stained with FITC conjugated anti-mouse CD45R/B220 
(Biolegend) or rabbit anti mouse IgA (Zymed, Invitrogen Life Technologies, Inc) 
respectively for 1 hour following manufacturers instructions. After washing with 
PBS (3 x 5min) each sections were treated with rhodamine conjugated goat anti 
rabbit IgG (US biologicals) for 1 hour. Cells were counterstained with 4, 6-
diamidino-2-phenylindole (DAPI) (Roche Diagnostics) according to the 
manufacturer’s instructions. The slides were mounted using mounting medium   
and visualized under fluorescence microscope (Carl Zeiss, Inc., Thornwood, 
USA). 
 
2.2.8. Oral immunization protocol and immune cell analysis in mesenteric 
lymph nodes (MLN) 
Four groups with eight C57BL/6 or Balb/c mice in each were immunized by oral 
gavage with either 108 wild type LGG, LGG-GFP, LGG-IL2-GFP or with PBS on 
days 0, 14 and 28 (Steidler et al. 1998). Sera and feces were collected on days 0, 
10, 24, 35 and 80. In a second set of experiments, on the 35th day the MLN from 
C57BL/6 mice were harvested and single cell suspensions were prepared for 
staining with antibodies to B220, IgA, CD4, CD8, CD3 (BD Pharmingen, USA) 
for flow cytometric analysis. About 1.0 x 104 cells were examined on a CyAnADP 
(Dako Cytomation, Sweden). Data was analyzed with Summit software (Dako 
Cytomation). 
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2.2.9. Intestinal fragment cultures from orally immunized mice. 
The Peyer’s patches were removed from the harvested small intestine and 
transverse colon of mice, washed with PBS to remove the fecal content and then 
100mg of tissue were incubated in 1ml of RPMI supplemented with 10 % FBS; 
100 U/ml penicillin; 100 µg/ml streptomycin; 0.25 µg Amphotericin B ( GIBCO); 
2 mM L-glutamine; 1 mM sodium pyruvate (GIBCO);  5 x 10-5 M 2-
mercaptoethanol (Merck) and 50 µg/ml gentamicin (Sigma) at 37ºC for 24 hours. 
Supernatants were collected and stored at -20 ºC for cytokines analysis. 
2.2.10. ELISA for total and GFP specific antibodies in serum and mucosal 
tissues 
Polystyrene microtitre plates were coated overnight at 4ºC with 50 ng/well of 
purified goat anti mouse IgG (Immuno pure- Pierce biotechnology Inc) or rabbit 
anti mouse IgA (Immunology Consultant laboratories, New berg, OR, USA) or 
IgM (Bethyl laboratories, Montgomery, TX, USA) or IgE (Biolegend, San Diego, 
CA, USA)  or recombinant GFP (Alpha diagnostic laboratories, San Antonio, 
USA) or PSA (Chemicon International) in PBS. Wells were blocked for 3 hours at 
room temperature using 3% BSA for IgG and 1hour at room temperature using 1% 
BSA for IgA, IgM, IgE and anti-GFP specific antibodies. Sera were tested at 
dilutions of 1/10,000 for IgG or 1/5000 for IgG1 or 1/1000 for IgG2a, IgA, IgM or 
1/100 for IgE or 1/500 for GFP antibodies. Fecal extracts or BAL were screened at 
dilutions of 1/500 for total IgA and 1/5 for GFP specific IgA. Intestinal fragment 
culture supernatant were also tested for total and GFP specific IgA. 
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Standard curves were produced using a dilution series of purified mouse IgG 
(Immuno pure- Pierce biotechnology Inc); IgG1, IgG2a (BD Pharmingen, San 
Diego, CA); IgA (Bethyl laboratories); IgM and IgE (BD Pharmingen, San Diego, 
CA.) and GFP or PSA  monoclonal antibodies (Chemicon, USA). For GFP 
specific IgA  ELISA ,GFP specific mouse IgA standard was not available, hence 
the values were expressed  in Optical density (OD).  Rabbit anti mouse IgG 
(DAKO, Glostrup, Genmark); IgG1 and IgG2a (Serotec, Kidlington, OX5 1GE, 
UK); goat anti mouse IgA (Immunology Consultant laboratories); IgM and IgE 
(Serotec) antibodies conjugated to (HRP) horseradish peroxidase was applied 
before color development using TMB substrate (Pierce biotechnology Inc). The 
absorbance was read at 450 nm; reference wavelength 570 nm (Tecan GENios/ 
Magellan). 
At 80th day of post primary nasal immunization, mice bladder, intestines and 
vaginal tissue were collected and homogenized in the presence of protease 
inhibitors (Protease inhibitor cocktail, Roche, Basel, Switzerland). Total protein 
and IgA concentrations were estimated using the Micro BCA protein assay kit 
(Pierce biotechnology Inc) and ELISA respectively.  
  2.2.11. Detection of anti lactobacillus antibodies 
An extract of lactobacillus protein was prepared as previously described for 
Lactococci (Wells et al. 1993). Lactobacilli were recovered from MRS medium by 
centrifugation following addition of NaCl to a final concentration of 1M. Cells 
were washed three times with wash buffer (100 mM Tris-HCl pH7.5, 5 mM 
MgCl2, 2mM EDTA, 1 mM PMSF) and each gram of cells (wet weight) 
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suspended in about 3-4 ml of ice cold wash buffer containing protease inhibitors (2 
µM leupeptin,1 µM pepstatin A and 0.1 mM PMSF). The cells were homogenized 
with 40-50 g of glass beads (0.10 mm diameter) for 2 x 30s. The glass beads were 
removed by glass filter and the homogenate centrifuged at 10,000 x g for 15 min to 
pellet the cell walls. The membranes were removed from soluble protein fraction 
by centrifugation at 144000 x g for 75 min at 4º C. ELISA plates were coated 
overnight with 100 ng/well of membrane extract in PBS at 4ºC and then blocked 
for 1 hour at room temperature with 1% BSA (Sigma). Serum, BAL fluid and fecal 
extract were tested for LGG specific antibodies. To compare the specific and non 
specific antibody induction the high antibody titer serum collected on day 35 was 
serially diluted to obtain approximately the same absorbance for both anti-LGG 
and anti-GFP ELISA and the titer differences were calculated by comparing the 
serum dilution factors. 
 
2.2.12. Cytokine analysis of BAL and intestinal fragment culture supernatant 
Cytokines (TNF IFNγ, IL2, IL4, IL6, IL10, IL12 and TGFβ) were analyzed with 
commercial ELISA kits (BD Biosciences or eBiosciences ). Briefly, 100 l capture 
antibody (Ab) diluted in coating buffer was added to each well, and incubated 
overnight (4oC). The plates were then washed three times with wash buffer (PBS 
with 0.05% v/v Tween 20) and blocked with 200 l assay diluent (RT, 1 hour). 
Following which, the plates were washed 3 times before the addition of 100 l 
standard or sample. Plates were incubated for 2 hour at RT. The plates were 
washed again, then 100 l working detector (biotinylated detection Ab and 
                                                                                                                                    
                                          
52
strepavidin-horseradish peroxidase conjugate (HRP) was added to each well (RT, 
1hour). The plates were then washed before 100 l TMB substrate solution (Pierce 
Biotechnology Inc., USA) was added to each well, and incubated in the dark (RT, 
30 min). 50 l stop solution (2N H2SO4) was added to each well to stop the 
reaction. The absorbance was read at 450 nm; reference wavelength 570 nm 
(Tecan GENios/ Magellan). 
 
2.2.13. Visualization of the bacteria after oral or nasal immunization 
2.2.13.1. Confocal or electron microscopy 
Twenty four hours after oral immunization, mice were anesthetized by 
intraperitoneal injection of ketamine (100 mg/kg) and xylazine (9 mg/kg) and 
perfused with a warm PBS followed by freshly prepared fixative mixture (2% 
paraformaldehyde + 3% glutaraldehyde) in a buffer system for 15 minutes.  After 
that, mice small intestines, cecum and large intestines were removed and some of 
them were snap frozen in isopentane (Sigma Aldrich) that was prechilled in liquid 
nitrogen. Cryosections (5-10 μm) of the specimens were directly visualized for 
green fluorescence under confocal microscopy (Carl Zeiss). For Transmission 
electron microscopy (TEM), tissues were cut into small pieces of 1 mm3 and 
immersed in the fixative (2% paraformaldehyde + 3% glutaraldehyde ) for 2 - 4 
hours at 4º C. Thereafter, tissues were rinsed in the same buffer (5% sucrose) and 
post fixed in 1 to 2% OsO4 ,pH 7.4 for 1 hour at room temperature. After washing 
in the buffer for 5 - 10 minutes, samples were dehydrated (25% ethanol, 5 min; 
50% ethanol, 10 min; 75% ethanol, 10 min; 95% ethanol, 10 min; 100% ethanol 
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10 min). After dehydration, the samples were transferred to 100% Acetone 10 min 
(twice with fresh acetone each time). The samples were incubated in ethanol-
araldite (1: 1) solution for 15 min, then overnight at room temperature in ethanol-
araldite (1: 6) solution. The following day, the samples were incubated for 1 hour 
each in 100% araldite at 40oC, 45oC, and 50oC. Finally the samples were 
embedded in pure araldite (60oC for 24 hours), then trimmed and sectioned with an 
Ultramicrotome (~80 nm thick sections) and viewed with an electron microscope 
(Phillips, Netherlands). 
 
2.2.13.2. Bacterial uptake in situ 
4-6 weeks old, female C57BL/6 mice were anesthetized by intra peritoneal 
injection of 100 mg/kg of ketamine and xylazine (9 mg/kg) per mouse. Around 10 
cm long segments of the small intestine of mice were ligated at both ends with 
surgical thread as described by Jang et al. 2004. GFP-expressing LGG (1 x 108 
CFU) were suspended in 1.0 ml of sterile PBS and inoculated into the loop and 
incubated in situ. One hour later, intestinal segments (without PP) were removed 
and extensively washed with cold PBS and RPMI medium 1640 containing 
gentamycin (100 μg/ml). Whole mounted intestinal segments were fixed in 4% 
paraformaldehyde followed by washing in 10% FBS in PBS, and M cells  and 
columnar epithelial cells were stained with rhodamine conjugated Ulex europaeus 
agglutinin (UEA-1, Vector laboratories) and Alexa fluor 633 conjugated Wheat 
germ agglutinin (WGA, Molecular probes, Invitrogen) respectively. Some 
intestinal parts were cryosectioned and stained for M cells or columnal epithelial 
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cells as described above. Tissue sections or whole-mounted small intestinal 
segments were viewed under confocal microscopy (Carl Zeiss).    
 
2.2.13.3. Tracking of GFP expressing LGG in lung after 24 hrs of nasal 
immunization 
Mice were euthanized one day after nasal immunization with LGG-GFP and lungs 
were harvested and cut into small pieces before being snap frozen in isopentane 
that was pre-chilled in liquid nitrogen. About 10 μm size cryosections were made 
and air dried on poly L-lysine coated slides. The slides were blocked in 3% H2O2 
dissolved in methanol for 15 min to inhibit the endoperoxidase activity. After 
blocking, the slides were washed then blocked in 5% normal rabbit serum for 60 
mins; washed and incubated with anti-GFP monoclonal antibody (Abcam Inc, 
Cambridge, USA)  overnight at 4ºC (1:500). The next day, the slides were washed 
before incubation with horseradish peroxidase labeled rabbit anti-mouse IgG 
(1:1000 dilution) for 1 hr. The slides were washed three times in 1 x PBS (5 min 
per wash) before a final rinse with Tris-Buffered Saline (TBS). Following which 
the slides were incubated in DAB solution for 10 mins then washed 5 times in 
TBS (5 min per wash). The slides were counterstained with methyl green for 5 min 
and then rinsed in ddH2O. Finally the stained slides were dehydrated in alcohol, 
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2.3 Ex vivo experiments  
 The murine transitional cell carcinoma cell line, MB49 was maintained in RPMI 
1640 supplemented with 10% fetal bovine serum (Hyclone), 2 mmol/L L-
glutamine, 50 units/ml penicillin, 50 µg/ml streptomycin (Invitrogen) at 37oC and 
5% CO2. MB49-PSA or MB49-GFP cells, were MB49 cells stably transfected with 
the human prostate specific antigen (PSA) or GFP  (Wu et al. 2004) and were 
maintained as described above with 0.2 mg/ml hygromycin (Invitrogen).  
 
2.3.1. Generation and purification of bone marrow-derived dendritic cells 
(BMDC) 
The procedure used to generate DCs from bone marrow cultures was as described 
previously by Mayordomo et al. 1995 with minor modifications. Briefly, the bone 
marrow was flushed from the long bones of the limbs of C57BL/6 mice, filtered 
through a 70 m cell strainer, and depleted of red cells with RBC lysis buffer. 
Bone marrow cells were plated in a culture dish (1.5 x 106 cells/ml; 10 ml/dish) in 
RPMI 1640 supplemented with 10% heat-inactivated FCS, 50 µM 2-
mercaptoethanol (ME), 1% penicillin, streptomycin, glutamine, MEM (Minimum 
essential medium), and 0.1% sodium pyruvate. Recombinant Murine Granulocyte 
Macrophage Colony Stimulating Factor (GM-CSF, eBiosciences) was added at a 
concentration of 20 ng/ml. Every 3-4 days, the culture media was changed and 
fresh mGM-CSF was added.  On days 8–10 DC were harvested by gentle 
pipetting. For purification, cells were centrifuged at 200 x g for 10 minutes and 
resuspended in 400 µl MACS buffer (PBS, pH 7.2, supplemented with 0.5% BSA 
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and 2 mM EDTA). To obtain high purity, Fc receptor blocking was done 
(CD16/32 antibody – Miltenyi biotec, Bergisch Gladbach, Germany) before 
adding 100 µl of CD11c microbeads (Miltenyi biotec). After CD11c microbeads 
were added, cells were mixed well and incubated for 15 minutes at 4 - 8°C. Cells 
were washed by adding 1-2ml of MACS buffer per 108 cells and centrifuged at 200 
x g for 10 minutes. The supernatant was removed and cells were resuspended in 
500 µl of buffer. A MS column was placed in the magnetic field of a suitable 
MACS Separator and rinsed with 500 µl of MACS buffer. The cell suspension was 
applied in 500 µl to 1ml volume and after it passed through, the column was 
washed with 3 x 500 µl of MACS buffer. Retained cells were eluted outside of the 
magnetic field and collected as dendritic cells. The purity of the dendritic cells 
were analyzed by flow cytometry BD FACS Canto (Beckton Dickinson, San Jose, 
CA) and FACSDiva software (Fig.2.2.b). 
 
2.3.2. Murine bone marrow neutrophils (BMN) purification    
Neutrophil purification from bone marrow cultures was done as described before 
with some modifications (Beauvillain  et al. 2007). The bone marrow was 
flushed from the long bones of the C57BL/6 mice limbs, filtered through a 70 
m cell strainer, and depleted of red cells with RBC lysis buffer. Cells were spun 
down at 2000 rpm for 5 mins and the supernatant was discarded. The cell pellet 
was resuspended in 200 µl of MACS buffer (cell count <108 for MS column). 
and 50 l of Anti-Ly6G Biotin was added (Miltenyi biotech) and mixed well, 
followed by incubation at 4 - 8oC for 10 mins. Then 150 l of MACS buffer and 
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100 l of Anti-Biotin Microbeads were added. Cells were mixed well and 
incubated for 15 minutes at 4 - 8oC. Cells were washed by adding 5-10ml of 
MACS buffer followed by centrifugation at 300 x g for 10 mins. The supernatant 
was removed completely and the pellet resuspended  in 500 l of buffer and 
loaded on a rinsed MS column was placed in the magnetic field of a suitable 
MACS Separator.  The column was washed with MACS buffer (3 x 500µl). 
Retained cells (neutrophils) were eluted outside of the magnetic field with 500 µl 
of MACS buffer. Cells were stained with FITC labeled Ly6G antibody and 
analyzed by flow cytometry (Fig 2.2.a)  
 
2.3.3. Bacteria – DC or neutrophils  co-culture 
BMDC or bone marrow derived neutrophils (5 x 105) were plated in 24 well 
plates in RPMI medium supplemented with 2Mm L-glutamine, 50U/ml of 
penicillin, 50 µM β-mercaptoethanol (sigma), 10% FCS and 10ng/ml of GM-
CSF ( eBiosciences).  Cells were incubated with recombinant LGG carrying IL2 
or IL15 or IL7 with or without PSA for 24 hours at a bacteria to cell ratio of 
100:1. Cells were washed in PBS three times and stained with the mAbs directed 
against the surface molecules CD86, CD80, CD83, CD11c, MHC II, and CD40 
or appropriate isotype-matched controls. Neutrophils were stained for CD86, 
CD83, CD11b or appropriate isotype controls. Analysis was performed with BD 
FACS DivaTM software. Supernatants from bacteria-DC or neutrophils co-culture 
were harvested and analyzed  by ELISA for mouse IL2, IL6, IL12p70, IL10, 
TNFα, and IFNγ .   
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2.3.4. Induction of PSA specific primary T cells  in vitro 
PSA specific primary T cells were generated as described before with some 
modifications (Rouse et al. 1994). T lymphocytes from naive C57BL/6 mice 
spleen were enriched by using STEM CELL-Easy sepR T cell isolation kit (Stem 
cell technologies, Vancouver, BC, Canada). A single cell suspension was 
prepared from spleen after mechanical disruption at a concentration of 1x108 
cells/ml in medium ( PBS with 2% FBS and 5% normal rat serum). Cells were 
placed in a 5 ml (12 x 75 mm) polystyrene tube or polystyrene round bottom 
tube (BD biosciences) to properly fit into the purple EasySep magnet. EasySep 
mouse T cell enrichment cocktail at 50 l/ml of cells (e.g. for 2 ml of cells 100 
l of cocktail) was added to the cells and incubated at 4° C for 15 minutes. Then 
biotin selection cocktail at 100 l /ml cells was added followed by gentle 
mixing. Sample was incubated at 4°C for 15 mins. Magnetic nanoparticles were 
mixed to ensure that they are in uniform suspension by pipetting vigorously for 5 
mins. Nanoparticles were added at 50 l /ml cells followed by incubation at 4°C 
for 15 mins. The cell suspension total volume was brought to 2.5 ml by adding 
the recommended medium without rat serum. Cells were mixed by gentle 
pipetting up and down 2 - 3 times. Then the tube was placed into the magnet 
(without cap) and left for 5 minutes. The magnet and tube were lifted and 
inverted (2 - 3s) to collect the fraction of cells that were not bound, in a new 5 ml 
polystyrene tube. The magnetically labeled unwanted cells remained bound 
inside the original tube, held by the magnetic field of the magnet. Usually the 
desired fraction was about 95 - 98% CD3 positive as seen in Fig. 2.2.c. Purified 
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T cells (1.0 x 107 cells per ml) were cultured with DC  infected (1.0  x  l05 cells 
per ml) with PSA secreting recombinant LGG to give responder-to-stimulator 
ratio-100:1 in 200 µl of LDA medium (NCTC 109 and RPMI 1640 [1:1]), 
supplemented with 10% heat-inactivated FCS, 10 mM Lglutamine, 1 mM 
oxalacetic acid, 0.2 U of bovine insulin per ml, and 50  µM of 2-
mercaptoethanol in 96-well U-bottom plates. The plates were incubated at 37°C 
under 5% CO2 . For positive control,   splenocytes from naive mice (60 x 106 
cells per flask) were incubated with  5 µg/ml of PSA specific CTL peptide ( 
VISNDVCAQV,  Proimmune, UK).  After 5 days, cells were used as effector 
cells for antigen presentation assay or CTL (cytotoxic lymphocyte) assay. 
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                                       Figure 2.2. Purity of the cells used for the bacteria stimulation experiments 
a) Purity of the bone marrow derived neutrophils after positively enriched by using Ly6G microbeads.  b) Purity of bone marrow derived 
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2.3.5. CTL and antigen presentation assays 
The antigen presentation assay was done as described before with some 
modifications (Cheadle et al. 2005).  Dendritic cells (5 x 105) were plated in 
24 well plate (total volume 2 ml and infected with recombinant LGG 
secreting IL2 or IL15 or IL7 or  PSA or IL2-PSA or IL15-PSA and or IL7-
PSA at a bacteria to cell ratio of 100:1 for 24 hours. After gentamycin 
treatment (200 g/ml for 2 hours) and three washes in PBS,  2 x 104 DCs 
were cultured with  5 x 105 purified T cells from naïve mice in 96 well U-
bottom plates  to give responder to stimulator ratio of 25:1. After 5 days, 100 
l of  medium  was removed for IL2 and IFNγ detection. For CTL assay 100 
l of medium was removed and 100 l of target cells were added and 
incubated for 5 hours. Syngenic mice splenocytes pulsed with PSA CTL 
peptide (2 - 5 hours) or MB49-PSA were used as target cells. The supernatant 
were harvested and LDH activity was determined by using CytoTox 96TM kit 
(Promega, Madison, WI, USA). The mean percentage of specific lysis of 
quadruplicate wells was determined using the following formula: % of 
cytotoxicity = [(experimental – effector spontaneous-target spontaneous) / 
Target maximum-target spontaneous)] x 100.  
 
2.3.6. Ex vivo ELISPOT assay  
Ex vivo ELISPOT assay was done as described before with some modification 
(Parent et al. 2005). On the 80th day, intranasally or orally immunized mice 
were euthanized and splenocytes were harvested. CD4+ T cells were positively 
enriched using CD4 microbeads (Miltenyi Biotec). The resultant cells were 
>85% CD4+ as determined by flow cytometry. 1 x 105 CD4+ T cells in DMEM 
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complete medium (Dulbecco’s Modified Eagle medium) were plated on mouse 
IFNγ ELISPOT plates (BD Pharmingen). Each well also contained 1 x 105 
mitomycin C (Sigma) pretreated splenocytes (50 g/ml) harvested from PBS 
administered mice and 10U of IL-2/ml. The plates were incubated at 37ºC with 
5% CO2 for 48 hours with or without 1g of recombinant GFP. For CD8 
ELISPOT, plates were loaded with 1 x 106 splenocytes per well, with GFP 
specific CTL peptide (H-2Kd HYLSTQSAL) (1 µg/ml) and 1 x 105 mitomycin 
C treated control splenocytes. Then the plates were incubated for 48 hours. The 
antigen specific IFN-γ secreting CD4 or CD8 T cells were visualized and 
enumerated.  
 
2.3.7. CTL response against MB49-GFP tumour cells 
CTL activity of spelnocytes from immunized mice was determined by 
measuring lactate dehydrogenase (LDH) activity released from lysed cells 
(Cytotox 96R, Promega). Briefly, 1 x 106 spleen cells were co-cultured with 1 
x 106 mitomycin-C treated  MB49-GFP cells and 1 µg/ml of  GFP specific CTL 
peptide (H-2Kd HYLSTQSAL, Proimmune, UK) in RPMI 1640 supplemented 
with 5% FBS, 50U/ ml penicillin, and 50 u/ml of streptomycin for 5 days. The 
splenocytes were recovered and used as effector cells against 1 x 104 viable 
MB49-GFP cells as target cells at a ratio of 1:1, 10:1 and 30:1. After 5 hours of 
culture, supernatants were recovered and LDH activity was determined. The 
mean percentage of specific lysis of quadruplicate wells was determined using 
the following formula: % of cytotoxicity = [(experimental – effector 
spontaneous-target spontaneous) / Target maximum-target spontaneous)] x 100 
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2.4. Statistical analysis 
All animal experiments were independently replicated at least twice whereas in 
vitro experiments were independently replicated at least thrice, each time in 
duplicates. Graphs were prepared using GraphPad Prism and statistical analysis 
was performed using one way ANOVA with post hoc Scheffe test (SPSS 
software).  A p value of < 0.05 was taken to indicate a significant difference.  
All graphical data was expressed as the mean ± SD (unless stated otherwise) of 
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3.1. Expression of the model antigen GFP with a cytokine in LGG 
The specific aim of this dissertation was to explore the potential of 
Lactobacillus rhamnosus GG (LGG) as antigen delivery vehicle. A model 
antigen GFP was expressed in LGG and to enhance the immune response, 
murine IL2 was also co-expressed with the antigen. GFP was cloned in the E 
.col i- Lactobacillus shuttle vector, pLP500 under the control of the  ldh 
promoter with or without murine IL2. To study the general or specific immune 
response elicited by mucosal immunization, mice were immunized orally or 
intranasally with LGG secreting GFP or IL2-GFP. Wild type LGG or PBS was 
administered as controls.   
 
3.1.2. Expression or co-expression of model antigen, GFP with murine IL2  
The supernatant from overnight cultures of LGG-GFP or LGG IL-2-GFP were 
collected to assess GFP and IL2 secretion and the bacteria were collected for 
analysis of bacterial numbers by plating. GFP expression in LGG-GFP and 
LGG-IL2-GFP was confirmed by flow cytometry and confocal microscopy 
(Figure 3.1). 
As the GFP expression in LGG-GFP or LGG-IL2-GFP was almost similar, 







                                                                                                                                    









































































Figure 3.1. GFP or IL2 expression in modified LGG (LGG-GFP or LGG-IL2-GFP) 
GFP fluorescence was visualized under confocal microscopy (scale bar 50 μm), a) control wild type LGG and b) LGG-GFP; c) Analysis of 
GFP expression in LGG-IL2-GFP by flow cyometry; d) Secretion of IL-2 vs bacterial cfu with time, the dashed line represents cfu/ml of 
bacteria and the solid line represents IL-2 secreted into the supernatant in pg/ml; e) Secretion of GFP in the culture supernatant- the dashed 
line represents LGG-GFP and solid line represents LGG-IL2-GFP and f) Intracellular expression of GFP or IL2- the dotted or solid line 
represents GFP or IL2 expression in LGG-IL2-GFP respectively and the dashed line represents GFP expression  in LGG-GFP.  
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Even though, the plasmid has a secretory signal sequence from the prt P gene 
of L. casei (Ho et al. 2005) for secretable expression, there was a significantly 
detectable level of internal expression as well.  The levels of IL-2 and GFP 
secreted in the culture media increased with bacterial CFU reaching a 
maximum at about 22 hours when the bacteria were at the end of the 
exponential phase and decreasing thereafter (Figure 3.1.d). Therefore the 
bacteria used for immunization were harvested after 22 hours of culture. At 
this point the total production (intracellular and secretory) of IL-2 and GFP 
was about 1.143 and 1.072 ng/ml respectively from 1.3 x 109 CFU/ml of 
LGG-IL2-GFP. GFP concentration in LGG-GFP was about 1.021 ng/ml at 22 
hours of culture (Fig 3.1.f). Only 1/5 of the total protein produced was 
secreted and the secretion of GFP from LGG-IL2-GFP and LGG-GFP was 
248 and 251 pg/ml respectively and the amount of IL2 secreted by LGG-IL2-
GFP was 265 pg/ml as seen in fig. 3.1.e. 
 
3.1.3. IL2 secreted by LGG-IL2-GFP is biologically active 
To analyze the biological activity of IL2 secreted by LGG-IL2-GFP, a CTLL-
2 proliferation assay was performed.  Culture supernatants from LGG-IL2-
GFP was harvested after 22 hours of culture and dialyzed against blank RPMI 
followed by ultra filtration to concentrate the protein. FBS was added to get 
10% FBS in RPMI and sterile filtered. CTLL-2 cells were harvested from 
stock cultures supplemented with IL-2 and washed twice by centrifugation. 
CTLL-2 cells were dispensed into 96 well assay plates (5 x 103 cells/well) and 
cultured for 20-24 hours in the presence of IL-2 or bacterial culture 
supernatant. Various concentrations of Human Recombinant IL-2 were used as 
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standard. To confirm the IL2 mediated proliferation, a blocking antibody to 
IL2R  was added with  bacterial culture supernatant. After 1 day of culture, 
20μl of CellTiter 96® AQueous One Solution Reagent, was added  and the 
assay plates were incubated for an additional 4 hour period. 490nm absorbance 
was recorded directly from the CellTiter 96® Assay plate. The bioactivity of 
















Figure 3.2. CTLL-2 proliferation assay. IL2-GFP-LGGculture 
supernatant was dialyzed against blank RPMI and concentrated by ultra 
filtration before determining its biological activity with a  CTLL-2 
proliferation assay. Media without IL2 was used as blank. IL2 induced 
proliferation was abolished in the presence of the blocking antibody to 
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3.1.4. Stability of transformed bacteria 
  The heterologous protein expression depends on the stability of the 
recombinant plasmid. Culturing recombinant bacteria in antibiotic selection 
ensures the survival of bacteria which possess the recombinant plasmid. 
Recombinant LGG may loose the plasmid at mucosal sites, since antibiotic 














Figure. 3.3. Divergent stability of recombinant plasmids in LGG in non 
selective environment.  LGG secreting GFP (a) or IL2-GFP (b)   were 
subcultured every day in  MRS broth with (dotted line) or without (solid line) 
erythromycin. Bacterial CFU in the daily culture was determined by plating 
bacteria on MRS agar plates with eryhtromycin.  
 
 
Though booster immunization may be helpful in colonization of recombinant 
LGG at mucosal sites, plasmid stability in a non-selective environment would 
determine the continuous antigen production from the bacteria at colonizing 
sites.  We analyzed the stability of IL2-GFP or GFP secreting LGG in a non-
selective environment by sub- culturing the bacteria every day in MRS broth 
with or without erythromycin and plating the bacteria on ery+ MRS plates to 
determine the number of bacteria that still have the plasmids.  Though 
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continuous propagation in non-selective media caused gradual plasmid loss 
both in GFP or IL2-GFP secreting LGG, the pLP500-GFP plasmid was more 
stable than the pLP500-IL2-GFP plasmid (Figure 3. 3). However, there was a 
50% reduction in bacteria carrying the IL-2-GFP plasmid only after 20 days of 
continuos culture.  
 
3.2. Survival and colonization ability of LGG after oral or nasal 
immunization. 
The main advantage of using a Lactobacillus  based vaccine is the ability of 
lactobacilli to colonize the mucosa. Therefore bacterial localization in lung or 
intestines; bacterial translocation to draining lymph nodes or spleen or liver 
and persistence after nasal and oral immunization were examined.  
 
3.2.1.  Translocation of modified LGG after nasal  or oral immunization 
To locate Lactobacilli after oral or nasal immunization with 1x108 CFU of 
bacteria the MLN (oral immunization) or NALT, CLN and Med.LN ( nasal 
immunization) were collected. For the analysis of systemic translocation, the 
spleen and liver were also collected. The tissues were homogenized and 
bacterial cfu determined by quantitative plating on Ery+ MRS agar plates. 
Bacterial load was determined at 24 hours, 48 hours and 1 week post-
immunization. Twenty-four hours after intranasal immunization, more bacteria 
were found in the NALT than CLN or Med.LN (Table 3.1). These bacteria 
were progressively and completely cleared from the NALT, CLN and Med.LN 
and no more bacteria were found after 1 week. No bacteria were detected in 
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the spleen or liver. Both modified Lactobacilli showed the same pattern of 
translocation.   
   After oral immunization many bacteria were found to be translocated to MLN. 
IL2-GFP secreting LGG translocated in higher numbers to the MLN after 24 
and were still present in significantly higher number after 48 hours (Table 
3.1). 
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Table 3.1 Translocation of recombinant LGG after oral or intranasal immunization 
                    Bacterial cfu/gm of tissue  
MLN  Spleen  Liver  
LGG 
expressing 
  24 hrs   48 hrs   168 hrs 
 (1 week) 
  24 hrs    48 hrs   168 hrs 
 (1 week) 
24 hrs   48 hrs   168 hrs 






















  GFP 
 
  GFP- IL2  
  96 ± 48 
 
 1308 ± 501*  
 0 
 
 67 ± 9*  
   0 
 
   0 
 
7 ± 11 
78 ± 41 
 0 
 
 15 ± 4  
   0 
 
   0 
 






   0 
 
   0 
 
NALT   CLN   Med.LN   
  24 hrs   48 hrs    168 hrs 
 (1 week) 
  24 hrs    48 hrs   168 hrs 
 (1 week) 
24 hrs  48 hrs  168 hrs 





































 9944 ± 1523 
 
10052 ± 1259  
144 ± 132 
 
140 ± 96  
   0 
 




  37 ± 11 
 
  37 ± 12  
  0 
 
  0  
   0 
 
   0 
 
110 ± 40 
 




   0 
 
   0 
 
Data represent mean cfu ± standard deviations 
* Statistically significant (p <  0.05) 
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3.2.2. Persistence of modified LGG after oral immunization at gut on 80th 
day. 
Lactobacilli were known to colonize the intestine. We examined LGG 
colonization at the end of the immunization schedule. Different colonization 
ability of LGG-GFP or LGG-IL2-GFP in the small intestines were analyzed on 
the 80th day post primary immunization (52 days after the last immunization) by 
quantitative plating (Table. 3.4).   
  Table 3.2. Different colonizing ability of recombinant LGG in oral 
immunization.  
  
  Data represent mean  ± standard deviations  
* Statistically significant (p< 0.05) compared to LGG-IL2-GFP.  
 
3.3. Tracking of recombinant LGG using GFP as visible marker in 
immunization  
Direct observation of the GFP expressing bacteria by fluorescence microscopy 
(Figure 3.4, a - d); immunohistochemical staining (Figure 3.4, e-h) and 
Transmission Electron Microscopy (Figure 3.5, a-f )  allow us to trace bacteria 
in intestinal sections or lung sections of mice fed with GFP or IL2-GFP 
expressing LGG. Though quantitative analysis was not done, It also will be 
possible to analyze the interaction of LGG with M cells by using a ligated-
intestinal-loop system to avoid in vivo dilution of the sample. 
Bacteria CFU/ml of small intestine homogenate  Immunization 





131 ± 32* 
144 ± 42* 
21 ± 8 
38 ± 19 
56 ± 24 
0 
12980 ± 1230* 
12120  ±  850* 
967 ± 117 
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Immunohistochemical staining of LGG in lung and confocal microscopic 
examination of intestine showed the bacterial persistence in lung or intestine. 
Transmission electron microcopic examination clearly showed the bacterial 
uptake in intestine. ( Figure 3.5, a-c).  However many bacteria especially IL2-
GFP secreting LGG were seen in intravascular region which was an 
uncharacteristic for lactobacilli (Figure 3.5, e&f ). Orally immunized bacteria 
are known to be taken up by M cells at peyers patches (Macpherson et al. 2004). 
However in our TEM study the bacterial uptake was found to be mediated 
through intestinal epithelial cells. Hence LGG uptake by M cells at intestinal 
villus was investigated by loop ligation method as described previously for 
Salmonella typhimurium (Jang et al. 2004).  
   Under anaesthesia mouse intestine was ligated near caecum and 10cm from 
caecum and bacteria was injected (LGG-GFP - 108 cfu) in to intestine. After 1 
hour mice were euthanized and intestine was harvested and stained for M cells 
and FAE. As seen in Figure. 3.6, few GFP fluorescing LGG were co-localized 
with M cells at intestinal villi which suggested M cell mediated LGG uptake at 
intestinal epithelium (Figure. 3.6) 
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    Figure 3.4.  Tracking of LGG-GFP ( a,b & e,f) or LGG-IL2-GFP (c,d & g,h) in mice intestine (a-d) and lung (e-h)  
    24hours  after of oral or intranasal immunization. Cryosections of orally immunized mice caecum (a-c) or small intestines 
    (d) were examined under confocal microscopy and compressed Z-stack of optical sections were taken.  Paraffin sections  
   of nasally immunized mice lungs were stained with Horseradish Peroxidase labeled anti-GFP  antibody followed by  
   detection with diaminobenzidine (DAB) substrate. Bacteria were stained brown   and were observed in the bronchiolar 
    linings. Figure (h) is the magnified view of the boxed region in figure (g). The scale bar for a) is 20 μm; for b and c it is  
   10 μm and for d it is 20 μm. For e, f, h the magnification is 2 x 20  and for g, the magnification is 2 x 10.  
 
e) g) f) h) 
a) b) d) c) 
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 Figure 3.5.  Visualization of recombinant LGG in mice intestine ultrathin sections 24 hrs after oral administration 
by Transmission Electron Microscopy (TEM). Mice intestines were sterilized with ampicillin by oral administration 
followed by immunization with 108 CFU recombinant LGG. After 24hrs, the small intestine, large intestine and caecum 
were processed and examined for LGG-GFP (a-c) or LGG-IL2-GFP (d-f) under TEM. The scale bar for a and b is 0.2 μm; 
for c and d it is 0.5 μm and for e and f it is 1 μm. Arrows indicate the uptake (a, c, d) and the presence of bacteria in the 
intravascular region (e and f). 
 
                
a) b) c) a)
e) d) e) f) 
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      3.3.1. Bacterial uptake in mice intestinal villus  
         a)                                                                  b)                                                                c) 
                 
  
Figure 3.6. Confocal microscopic view of villous epithelium. Villus epithelium was stained for M cell and columnar epithelial 
cell-with UEA-1-TRITC (Ulex europaeus agglutinin) and WGA- Alexa fluor 633 (Wheat germ agglutinin) respectively. Whole 
mount preparation of small intestine (a & b) or cryosection of the intestinal segment (c). M Cells were stained by UEA-1 (red, 
arrow), enterocytes by WGA (blue), and goblet cells by UEA-1 and WGA (red-blue mix, arrowhead). LGG-GFP ( a&b) or LGG-
IL2-GFP (c)  were seen co-localized with M cells(◄). The scale bar for a and b is 20 μm; for c 10 μm. 
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Summary I 
Though the recombinant LGG were able to secrete GFP or IL2-GFP, the level of 
secretion was about 240 pg only. Moreover the secretion was not 100% and the 
majority of the recombinant protein was intracellular. However IL2 secreted as 
IL2-GFP fusion protein by recombinant LGG was biologically active.  
Recombinant LGG were able to colonize the intestine and lung after oral or 
nasal immunization. So the colonized recombinant LGG would secrete antigen 
which will be continuously taken up by dendritic cells. Live bacteria were 
isolated after 24 hours of oral or nasal immunization from mesenteric lymph 
nodes or NALT respectively. Interestingly IL2-GFP secreting LGG were 
translocated in higher numbers than GFP secreting LGG. Confocal microscopic 
examination of orally immunized mice intestine showed LGG were taken up by 
M cells. Transmission electron microscopic analyses also showed bacterial 
uptake in intestines.   
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3.4. Mucosal  immunization with recombinant LGG  
For mucosal immunization, the oral and nasal routes were examined. C57BL/6 
and Balb/c mice were used to study the total or antigen specific immune 
response after oral immunization while the nasal immunization was performed 
only on C57BL/6 mice. Feces (oral immunization) or BAL fluid (nasal 
immunization) and sera were collected on days 0, 10, 24, 35 and 80 to study the 
mucosal and systemic immune responses respectively (Figure 3.7). 
 
 
Figure  3.7. Oral or nasal immunization and sample collection schedule  
Primary immunization begins on Day 0. 
 
 
3.4.1. Systemic antibody production- general and specific after oral 
immunization 
There was no significant increase of total serum IgG or IgA in either mice strain.  
As shown in Figure 3.8 (a - d). From the 24th day onwards, GFP specific IgG 
levels were significantly increased in both C57BL/6 and Balb/c mice immunized 
with modified LGG and on 35th day the IgG titres were significantly higher in 
LGG-IL-2-GFP immunized mice compared to the other groups (Figure 3.8 e&f 
).  
Day 10  Day 24  Day 35  
  Day 80  
(Temination) Pre immune 
Primary  1st booster  
Day 0  Day 14  Day 28  
2nd booster 
Days on which mice received immunization 
Timing of serum and BAL or feces collection 
































Figure 3.8. Total and GFP specific systemic immune induction in oral 
immunization. 
Total and GFP specific serum IgG or IgA in C57BL/6  and Balb/c mice after 
oral immunization with modified LGG, wild type LGG and PBS. Eight mice 
from each group were inoculated on days 0, 14 and 28 with 108 modified 
LGG-GFP (angled stripes) or LGG-IL2-GFP (shaded) or wild type LGG 
(black) or with PBS (clear).  Graphs  a, c and e) represent total IgG, IgA and 
GFP pseciifc IgG in the sera of C57bL/6 mice. Graphs b,d and f) represent 
total IgG, IgA and GFP specific IgG from Balb/c mice. 
  *denotes statistical significance from PBS and LGG and ** indicates       
statistical significance from PBS, LGG and LGG-GFP (p< 0.05). Data are 
represented by the mean ± SEM in each group.  
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3.4.1.1. Local  antibody production- general and specific  
Secretory IgA (sIgA) levels increased significantly from day 10 and day 24 
onwards in C57BL/6 and Balb/c mice respectively after immunization with 
LGG (Figure 3.9 a & b). The IgA antibody titers remained elevated 52 days 
after the last booster dose (day 80).   GFP specific sIgA was also increased in 
fecal extracts from 24th or 10th day onwards in    C57BL6 or Balb/c mice 
respectively (Figure.3.9 c&d). By the 35th and 80th days in the C57BL/6 mice 
the titre was significantly higher in mice immunized with LGG-IL2-GFP 























Figure 3.9. Total and GFP specific mouse IgA  in fecal extracts of 
C57BL/6 or Balb/c  mice after oral immunization with modified LGG, 
wild type LGG and PBS. a&b) Total mouse IgA in fecal extracts of 
C57BL/6 or Balb/c  mice respectively. 
c&d) GFP specific IgA in C57BL/6 and Balb/c mice after oral immunization. 
LGG-GFP (angled stripes) or LGG-IL2-GFP (shaded) or wild type LGG (black) 
or with PBS (clear). * denotes statistical significance from PBS and LGG and 
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** indicates statistical significance from PBS, LGG and LGG-GFP (p< 0.05). 
Data are represented by the mean ± SEM in each group. 
 
 
3.4.1.2. IL2 co-expression enhanced GFP specific Ig production  
The fecal extracts collected on 35th day were serially diluted to obtain 
approximately the same absorbance for total IgA/IgG and GFP IgA/IgG on the 
ELISA. The dilutions producing the same absorbance for GFP and total 
IgA/IgG were expressed as a percentage of the dilution of GFP over the dilution 
of total IgA/IgG. Similarly, the dilutions producing the same absorbance for 
GFP and LGG were used to determine the relative amount of GFP to LGG 
specific antibodies (fold difference).  
Immunization with LGG-IL2-GFP and LGG-GFP resulted in 25 and 10 fold 
more GFP specific IgG and 5 and 2 fold more GFP specific IgA production in 
C57BL/6 mice whereas in Balb/c the ratios were lower primarily due to a higher 









Figure 3.10. IL2 co-expression enhances GFP specific IgG induction. 
At the 35th day of post primary immunization sera were analyzed for GFP or 
LGG specific IgG. a). Fold difference of GFP Vs  LGG specific serum IgG 
induction in C57BL/6 mice. b) Fold difference of GFP Vs LGG specific IgG in 
Balb/c mice. Anti-GFP IgG (angled stripes) and anti-LGG IgG (black) in mice 
inoculated with  LGG-GFP and anti-GFP IgG (shaded) and anti-LGG IgG 
(clear) in LGG-IL2-GFP inoculated mice. The difference in GFP and 
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Lactobacillus specific antibody levels were determined by comparing the 
dilutions of each required to obtain the same OD at 450 nm. 
 
 
The mean percentage of GFP specific IgG (GFP specific IgG/Total IgG X 100) 
in LGG-IL2-GFP immunized mice was about 0.036 and 0.037 compared to 
0.023 and 0.021 in LGG-GFP immunized C57BL/6 and Balb/c mice 
respectively. The percentage of GFP specific IgA was also higher in IL2-GFP-
LGG immunized mice and was 0.063 and 0.050 compared to 0.011 or 0.012 in 
LGG-GFP immunized C57BL/6 and Balb/c mice respectively (Table. 3.1).  
 
3.4.1.3. Analysis of GFP specific IgA and cytokines in intestinal fragment 
cultures  
At day 35 the small and large intestine were harvested and 100 mg of tissue 
fragments were placed in culture media. After 24 hours, the culture supernatant 
was analyzed for total IgA, GFP specific IgA, IL2, IL6, IL4, TNFα, IFN and 
TGFβ1. Total IgA production was increased in both wild type and modified LGG 
immunized mice and it was significantly greater in the large intestine of LGG-
IL2-GFP immunized mice than in PBS or LGG immunized mice respectively 
(Table. 3.2). Cultures of the small intestine, from LGG-IL2-GFP immunized 
mice produced a higher percentage of GFP specific IgA (0.063) compared to 
LGG-GFP (0.042) immunized C57BL6 mice. Similarly in the large intestines 
the ratio of GFP specific IgA was 0.02 for LGG-IL2-GFP immunized mice 
compared to  0.013 for LGG-GFP immunized C57BL6 mice.  
 There was no detectable IL2 or IFN. In LGG-IL2-GFP immunized mice small 
intestine culture, IL6 production was significantly higher and by contrast, 
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TGFβ1 levels were significantly lower when compared to PBS or LGG 
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     Table 3.3. Cytokine and IgA levels in intestinal culture supernatant  
 
 Data represent mean % of cells ± standard deviations  
* Statistically significant (p< 0.05) compared to PBS and LGG administration  




TNFα (pg/ml) IL6 (ng/ml)   sIgA (μg/100 g of tissue)       TGFβ (ng/ml)  Group 





9.3 ± 3.6 
4.2 ± 3.7 
11.1 ± 1.1 
9.9 ± 6.8 
6.1 ± 1.9 
14.2 ± 4.1 
10.7 ± 5.1 
20.1 ± 10.6 
0.09 ± 0.06 
0.12 ± 0.07 
0.23 ± 0.13 
0.63 ± 0.30* 
0.53 ± 0.14 
0.90 ± 0.15 
0.91 ± 0.39 
0.99 ± 0.31 
15.3 ± 2.2 
31.1 ± 6.7 
35.0 ± 4.1 
38.0 ± 6.8 
 
0.8 ± 0.1 
2.1 ± 1.0 
8.6 ± 4.8 
12.8 ± 7.0* 
 
7.78 ± 2.50 
6.21 ± 3.02 
6.02 ± 2.97 
1.65 ± 1.07* 
2.63 ± 0.21 
2.84 ± 0.20 
1.84 ± 0.28♦ 
3.39 ± 0.69 
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3.4.1.4. IFNγ ELISPOT for antigen specific CD4 and CD8 T cell responses 
To monitor the induction of CD4 and CD8 antigen specific T cells, an IFN- 
Elispot assay was performed on splenocytes isolated on days 35 and 80. 
Increased IFNγ secreting CD4+ or CD8+ T cells were seen after modified LGG 
immunization  
(p< 0.05) in both C57BL6 and Balb/c mice. LGG-IL2-GFP immunization 
generated significantly higher GFP specific CD8+ T cells (187 ± 31) than 
LGG-GFP (90 ± 25) in C57BL6 mice at day 35. A similar response, 121 ± 23 
and 69 ± 11 CD8+T cells from LGG-IL-2-GFP and LGG-GFP immunized 















































































































   
 
 
            
              
 
Figure  3.11. IFN- ELISPOT for the analysis of GFP specific CD4+ or 
CD8+ T cells   More expln here 
 GFP specific CD4+T  or CD8+ T cell responses in C57BL6 (a&c) or Balb/c 
(b&d) mice. * indicates statistical significance from PBS and LGG immunized 
mice and ** indicates statistical significance from PBS, LGG and LGG-GFP 
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 3.4.1.5. Immunization with LGG-GFP and IL2-GFP-LGG produced a GFP 
specific CTL response 
  A CTL assay was performed on splenocytes from immunized mice at day 35. 
Splenocytes were stimulated in vitro with mitomycin C treated MB49-GFP cells 
and GFP specific CTL peptide. Stimulated splenocytes were then tested for 
recognition and lysis of fresh viable MB49-GFP cells. As shown in figure.3.12, 
spleen cells from mice immunized with LGG-IL2-GFP or LGG-GFP had 
significant CTL activity compared to LGG or PBS immunized mice. LGG-IL2-
GFP immunized mice produced significantly more CTL activity than LGG-GFP 












Figure  3.12.  Induction of GFP specific CTL response in splenocytes of 
mice immunized with recombinant LGG.  
Four mice per group immunized via the oral route on days of 0, 14 and 28 with 
either PBS or wild type LGG or LGG-GFP or LGG-IL2-GFP were killed on day 
35. Splenocytes from immunized mice were pooled and co-cultured with 
mitomycin C treated MB49-GFP  cells and CTL peptide of GFP for 5 days. 
These splenocytes were used as effector cells and live MB49-GFP cells served 
as target cells. The assay was performed at the following effector to target (E:T) 
ratios (1:1,10:1,and 30:1). Specific lysis was determined by quantitative 
measurements of LDH. 
* indicates statistical significance from PBS and LGG immunized mice and 
** indicates statistical significance from PBS, LGG and LGG-GFP (p <0.05). 
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3.4.1.6. Phenotyping of mononuclear cell subsets in MLN after oral 
immunization 
Single cell suspensions from the MLN were prepared from the mice on the 35th 
day after primary immunization. Both wild type and modified LGG 
immunization increased the number of CD4+, CD8+ T cells and IgA+B cells in 
MLN compared to mice receiving PBS. LGG-IL2-GFP immunization induced 
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Data represent mean % of cells ± standard deviations  
























12.1 ± 2.15 
18.7 ± 4.47 
18.1 ± 2.90 
20.0 ± 2.67* 
17.7 ± 2.84 
35.9 ± 4.34* 
35.2 ± 3.48* 
36.8 ± 3.30* 
20.6 ± 1.64 
38.6 ± 4.50* 
38.8 ± 4.60* 
38.0 ± 2.22* 
73.7 ± 3.14 
78.7 ± 4.41 
82.3 ± 4.57 
86.0 ± 7.04*  
25.9 ± 3.26 
28.3 ± 2.94 
28.3 ± 5.77 
30.1 ± 3.81 
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Summary II 
 In this present study both recombinant LGG were shown to be able to elicit 
mucosal and systemic humoral responses after oral immunization in both 
C57BL/6 and Balb/c mice. Oral immunization of LGG elicited a sustained 
mucosal IgA induction and ex vivo culture of the intestines also showed a higher 
IgA level even 56 days after the last booster immunization. Lactobacillus 
delivery of GFP (approximately 0.1 ng) resulted in approximately 0.3 g/ml of 
GFP specific IgG antibodies being produced from LGG-GFP, while co-delivery 
of IL2 and GFP resulted in more antibody production namely 0.5 g/ml of GFP 
specific antibodies.  Our data indicates that a low level of secreted IL2 
(approximately 20 pg) is sufficient to produce significant adjuvant effects a 1.6 
fold increase in antibody production. The increased level of anti-LGG antibodies 
was not as great as the increase in GFP antibodies produced by the IL-2 fusion 
protein. Thus Lactobacilli are excellent delivery vehicles as they do not evoke a 
strong antibody response against themselves. There were increased GFP specific 
CD8+T cells in the recall assay and these were increased by IL2 co-expression. 
The CD8 T cells were cytotoxic to MB49 cells secreting GFP. The results of this 
study showed the beneficial effect of IL2 expression as a fusion protein with an 
antigen to elicit enhanced local and systemic humoral immune response as well 
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3.4.2. Nasal Immunization. 
Previous results with Lactobacillus plantarum expressing human papilloma 
virus 16 (HPV-16) E7 antigen demonstrated that intranasal route immunization 
was more effective than intragastric immunization (Cortes-Perez et al. 2007). As 
the choice of route of immunization is a crucial step in developing live mucosal 
vaccines, the immune induction elicited by nasal immunization was compared 
with the results obtained in oral immunization. 
 
3.4.2.1. General and specific antibody induction in nasal immunization 
Nasal immunization results in brisk and sustained induction of serum IgM, IgA, 
IgG and mucosal IgA (Waldo et al, 1994). Moreover intranasal co-
administration of  lactobacilli with cow’s milk allergen prevented the mice from 
sensitization (Cortes-Perez et al, 2007). Hence serum IgM, IgG, IgA and IgE 
were measured after nasal immunization.  The serum IgA levels (Figure 3.13 a) 
increased after the priming dose and were significantly increased by day 35 
(LGG-IL2-GFP) and remained high at day 80 (both modified microbes). There 
was a slight increase in total serum IgG (Figure 3.13 b) and IgM antibodies (data 
was not shown) but it was not statistically different from PBS or LGG 
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Figure 3.13. Systemic immune response in C57BL/6 mice after nasal 
immunization with of PBS  or  LGG or LGG-GFP or LGG-IL2-GFP. a, b,  
represent the mouse serum IgA, IgG induced  after nasal immunization  with 
LGG-GFP (angled stripes) or LGG-IL2-GFP (shaded) or wild type LGG 
(black) or PBS (clear) and c) represents the serum IgG1/IgG2a  ratio.  
* denotes statistically significant with PBS or  LGG immunization. (p <0.05). 
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GFP specific IgG titers increased rapidly (Figure 3.14), IL2 significantly 
increased GFP specific IgG production. The GFP specific IgG1/IgG2a ratio 
initially increased due to increasing IgG1 levels and decreased later as IgG2a 
levels increased (day 35 maximal, Fig. 3.14.b). GFP specific IgA in serum 
increased rapidly and with similar kinetics and profile as total IgA. Anti-GFP 
IgA levels were significantly increased in mice immunized with LGG-IL2-GFP 
compared to the other groups as seen in Figure 3.14.c. Similarly, anti-GFP sIgA 
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         c)                                                                d) 




       









Figure 3.14.  GFP specific local or systemic immune response induced in 
serum or BAL in C57BL/6 mice after nasal immunization with of LGG or 
modified LGG.  
a) GFP specific IgG  b) GFP specific IgG1/IgG2a  c) GFP specific IgA induced 
in serum. d) Total sIgA and e) GFP specific IgA induced in BAL. LGG-GFP 
(angled stripes) or LGG-IL2-GFP (shaded) or wild type LGG (black) or PBS 
(clear)  
* denotes statistically significant with PBS or  LGG immunization and  
 ** denotes statistically significant with PBS or LGG or LGG-GFP 
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3.4.2.2.  Immune induction at ectopic mucosal tissues 
Nasal immunization also induced IgA secretion in other mucosal sites as well. 
IgA secreted in intestines particularly from LGG-IL2-GFP immunized mice 
were statistically significant with PBS immunized mice as seen in Fig3.15.a.  
Though the OD for GFP specific IgA in modified LGG immunized mice vaginal 
mucosa was very low, it was  statistically significant with wild type LGG 
immunized mice ( Fig 3.15.b). 
 
a)                                                                       b) 







Figure 3.15. Total and GFP specific IgA produced  at the intestinal(I), 
bladder(B),  and Vaginal mucosa (V) at the 80th day after nasal 
immunization. a) Total mouse IgA and b) GFP specific IgA. Tissues. * 
denotes statistical significance from PBS and LGG and ♦  denotes 
statistical significance from PBS, p<0.05. Data are represented by the 
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3.4.2.3. Antibody induction by intranasal immunization with LGG-IL2-
GFP was more antigen specific 
At day 35, immunization with LGG-IL2-GFP and LGG-GFP induced 
approximately 32 and 24 times more GFP than LGG specific IgG or 12 and 10 
fold more anti-GFP IgA relative to anti-LGG IgA antibodies in serum or BAL 
respectively (Fig 3.16).  
  






Figure 3.16. Analysis of  GFP Vs LGG specific antibody induction  
At the 35th day post primary immunization, serum or BAL were analyzed for 
GFP or LGG specific IgG or IgA respectively. a). Fold difference of GFP Vs  
LGG specific serum IgG induction in serum. b) Fold difference of GFP Vs LGG 
specific IgA in BAL. Anti-GFP IgG or IgA (angled stripes) and anti-LGG IgG 
or IgA (black) in mice inoculated with  LGG-GFP and anti-GFP IgG or IgA 
(shaded) and anti-LGG IgG or IgA(clear) in LGG-IL2-GFP inoculated mice. 
The difference in GFP and Lactobacillus specific antibody levels were 
determined by comparing the dilutions of each required to obtain the same OD 
at 450 nm. 
 
 
3.4.2.4. Analysis of total and GFP specific IgA in CLN, NALT and lung  
tissue    ex  vivo 
At the 35th day post primary nasal immunization, the CLN, NALT and lung 
tissues from immunized mice were harvested and cultured ex vivo for 24 hours. 
CLN and lung cells in LGG immunized mice produced a high level of IgA or 
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IgG (Fig 3.17). In LGG-IL2-GFP immunized mice, lung  and CLN cells 
produced a higher GFP specific IgA or IgG which was statistically significant 
from LGG immunized mice as seen in figure 3.17. c&d.  









Figure  3.17. Total  or GFP specific Ig induction in ex vivo culture.  
At the 35th day post primary immunization, CLN, NALT and lung tissues of the 
mice immunized with LGG-GFP (angled stripes) or LGG-IL2-GFP (shaded) or 
wild type LGG (crossed stripes) or PBS (clear) were aseptically harvested and 
cultured ex vivo for 24 hours and supernatants were analyzed for total (a & b) or 
GFP specific IgA or IgG (c & d). For lung and CLN, 100mg of tissues were 
cultured and for NALT, the whole tissue was cultured. * denotes statistical 
significance from PBS, ** denotes statistical significance from PBS and LGG 
and *** denotes statistical significance from PBS, LGG, LGG-GFP, p <0.05. 
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3.4.2.5. Analysis of inflammatory cells in BAL after nasal immunization. 
LGG-IL-2-GFP immunized mice had significantly more lymphocytes in the 
BAL than LGG immunized mice (Fig 3.18e). Macrophage and neutrophil 
numbers did not differ between the different LGG groups. By the 80th day, the 
pattern of immune cells was almost back to that in PBS treated mice except for 
lymphocytes which, though much lower than at day 35, were significantly 
higher in mice immunized with modified LGG (Fig 3.18f). 
        a)                            b)                            c)                           d)  
              
                                            
             
                                                    




Figure 3.18. Immune cells in BAL fluid after immunization with modified 
LGG or wild type LGG or PBS. On days 35 and 80, BAL fluid cells from 
immunized mice were cytospined and H & E stained. Cells were visualized and 
examined under microscopy (magnification 2 x 20 - a to d). M - monocytes, L - 
lymphocytes, N- neutrophils. The number of macrophages/monocytes (clear), 
lymphocytes (striped) and neutrophils (shaded) in 5000 cells were enumerated. 
Immune cell populations in e) day 35 and f) day 80 BAL fluid samples are 
shown. * indicates statistical significance from PBS and LGG administration 
and ♦ indicates statistical significance from PBS administration. Data are 
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3.4.2.6. Cytokine levels in BAL  on the 35th day after nasal immunization 
At day 35 only IFN- was significantly increased in the BAL of mice 
administered LGG-IL2-GFP compared to mice given LGG-GFP, LGG  and PBS 
(Table 3.5). While TNFα was significantly greater in the BAL of both modified 
LGG compared to LGG and PBS administered mice. IL12, IL4 and IL10 levels 
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     This experiment was repeated twice and the data shown here is the mean ± standard deviation from one experiment.  
    ** Statistically significant (p< 0.05) compared to PBS, LGG, LGG-GFP administration 
    *Statistically significant (p< 0.05) compared to PBS, LGG administration  




                                     Cytokine levels in lung lavage fluid (pg/ml) Immunization 





PBS  68.0 ± 22.02 
 
392.6 ± 179.3 74.15 ± 7.38 81.5 ± 26.07 158.5 ± 32.46 15.66 ± 7.78 
LGG 
 
107.74 ±41.93 501.49 ± 111.15 
 
81.47 ± 32.49 
 
 
142.6 ± 15.64 182.8 ± 28.89 11.41 ±4.23 
LGG-GFP 158.48 ± 30.61 ♦ 
 
 
513.68 ±  142.88
 
105.89 ± 31.47 
 
137.5 ± 19.03 172.0 ± 17.43 11.62 ± 4.15 
LGG-IL2-GFP 186.05 ± 34.13 * 649.19 ± 71.13 177.87 ± 32.68 ** 189.21 ± 19.95 ♦ 177.3 ± 13.95 8.74 ± 5.88 
    Table 3.5 . Cytokine levels in fluid from lung lavage on the 35 th day after nasal immunization 
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3.4.2.7. Phenotyping of cells in CLN and NALT after intranasal immunization  
Single cell suspensions from the CLN and NALT were prepared from the mice on 
days 10, 24 and 35. Though the differences are small, the modified LGG 
immunization elicited significantly higher numbers of IgA+ B cells and CD8+ T 
cells in CLN. A Significant difference in IgA+ B cell numbers was only observed at 
day 35 in NALT with LGG-IL2-GFP imunization (Table 3.6). While LGG 
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                      Data represent mean absolute  number or  % of cells ± standard deviations  
                    * Statistically significant (p< 0.05) compared to PBS and LGG administration  
                     ♦ Statistically significant (p< 0.05) compared to PBS administration 
                                        CLN x106  cells NALT 
% of cells 
Immunization 






1.38 ± 0.13 
2.20 ± 0.14 
3.03± .26* 
3.53± .36* 
1.17 ±  0.11 
1.87 ±  0.12♦ 
2.00 ±  0.17♦ 
2.06 ±  0.21♦ 
1.61 ± 0.11 
2.14 ± 0.14 
2.59 ± 0.22* 
2.58 ± 0.26* 
1.00 ± 0.09 
1.88 ± 0.12♦ 
1.38 ± 0.12♦ 
0.91 ± 0.05 
13.6 ± 4.12 
 
22.6 ± 5.16 
 
40.0 ± 13.66 
 
56.3 ± 1.29* 
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3.4.2.8. Histopathological analyses and immunohistochemical staining of 
the   lungs from immunized mice 
         As the lung are not the usual site for LGG, it was necessary to determine if nasal 
immunization with LGG would lead to tissue damage. Lung tissues were 
examined for signs of immune cell accumulation and fibrosis. At the 35th day 
(Fig 3.19.a) there was increased cellular infiltration in the peribronchiolar 
regions of the lung tissues, isolated from LGG, LGG-GFP and LGG- IL2-GFP 
immunized mice compared to PBS immunized mice. However the cellular 
infiltrates were reduced by day 80 (Fig 3.19.b). Immunohistochemical staining 
of lungs from immunized mice showed the nasal immunization of wild type 
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             Figure 3.19. Histopathological analyses and immunohistochemical 
staining of IgA secreting B cells in murine lung tissue. 
            On days 35 and 80, lungs were harvested from immunized mice and fixed in 
10% formalin. The paraffin embedded tissue sections were H & E stained and 
evaluated for cellular infiltration or inflammatory changes (boxed region). 
Tissue sections of the mice immunized with PBS , LGG , LGG-GFP  and  
LGG-IL2-GFP  which were harvested on the 35th  (a) and 80th  (b) days. On 
80th day lungs from mice immunized with PBS or LGG or LGG-GFP  or 
LGG-IL2-GFP  were cryopreserved and 5-10µm size frozen sections were 
stained with rhodamine labeled anti mouse IgA and FITC labeled anti mouse 
B220 antibodies followed by counter staining with DAPI. Sections were 
examined under confocal microscopy (c). Yellow fluorescent B220+ IgA+ 
cells were easily distinguished from red fluorescent IgA+ or green fluorescent 
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3.4.2.9. Analysis of mouse inflammatory cytokines and receptors with 
microarray in lungs of immunized mice  
One lung was harvested from each group at the 35th day  post primary 
immunization to  study the mRNA profile of inflammatory cytokines, chemokines 
and their receptors. At 35 the day Ccl17,Ccl2, Ccl25, Ccl6, Ccr2, Fcgr1, Cxcl5, 
Il10, Il16, Il1r1, Il20, Il2rg, and Il5ra genes were differentially expressed in the 
lungs of the mice immunized with PBS or LGG or LGG-GFP or LGG-IL2-GFP 
(figure 3.20 and Table 3.7).  
        Control(PBS)                  LGG                   LGG-GFP             LGG-IL2- GFP 
           
    
                Figure 3.20 . X - Ray images of cRNA array – at 35th day-   Gene expression   
profiling of the mouse lung harvested at 35th day of post primary immunization 
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Table  3.7. List of the genes expression upregulated on oligo array. 
 
Fold increase on oligoarray at 35th day of 

















































































  Ccl25, Ccr2, Fcgr1 and Il16 (bold and underlined) up regulation were confirmed with 
PCR. Apart from the genes screened in oligo array, IP-10 and CD8a genes were also 
analyzed with PCR.  
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At the 35th day post primary immunization IL16, CCR2, IP10, CD8a and 
CCL25 mRNA transcripts were significantly increased after LGG-IL2-
GFP immunization. IL16 expression in LGG-IL2-GFP immunized mice 
lung was statistically significant with PBS immunization (Table 3.8). 
CCR2, IP10, CD8a or CCL25 expression in LGG-IL2-GFP immunized 
mice lung was statistically significant from PBS, LGG, LGG-GFP or PBS, 




                            Rps27a 
        IL16                   
        CCR2                                                  
      CCL25                                                      
       FcgR1                                        
       CD8 
       IP10 
        
                PBS         LGG-IL2-GFP        LGG           LGG-GFP 
 
 
Figure 3.21.  Gene expression changes induced by the recombinant or 
wild type LGG in lung.  
To confirm the array data cDNA was synthesized from total RNA isolated 
from the lungs of PBS (n = 4), LGG (n = 4), LGG-GFP (n = 4) and LGG-
IL2-GFP (n = 4) immunized mice on the 35th day post primary 
immunization. PCR was performed to confirm and identify gene 
expression changes. The following genes were found to be differentially 
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Data expressed is relative to Rps27a; ‘-‘ indicates not detectable. Data is 
presented as mean ± SD. * denotes statistically significant with PBS, ** denotes 
statistically significant with PBS and LGG and *** denotes statistically 
significant with PBS, LGG and LGG-GFP. P  value <  0.05. 
Gene expression was normalised with Rps27a levels. The PCR product band 
intensities were quantified with SynGene GeneTools analysis software. The 

























                                          Treatment Gene 








0.292 ± 0.280 
- 
- 
0.054 ± 0.064 
0.085 ± 0.026 
- 
0.656 ± 0.494 
- 
- 
0.061 ± 0.013 
0.279 ± 0.029 
- 
0.808 ± 0.244 
0.014 ± 0.007 
- 
0.162 ± 0.093 
0.166 ± 0.042 
0.005 ± 0.009 
1.144 ± 0.2 * 
0.156 ± 0.05*** 
0.309 ± 0.36 
0.427 ± 0.27** 
0.806 ± 0.16*** 
0.161 ± 0.12*** 
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3.4.2.10. Induction of GFP specific cellular immune response by nasal 
immunization 
Antigen specific cellular immune was analyzed by ex vivo ELISPOT assays for 
IFNγ secreting CD4+ or CD8+ T cells on splenocytes isolated on day 80 or 35 
respectively. Increased IFNγ secreting CD4+ (Figure 3.22.a) and CD8+ T cells 
(Figure 3.22.b) were seen after modified LGG immunization (p <0.05). LGG-
GFP or LGG-IL2-GFP immunization generated about 314 ± 129 or 401 ± 109 
GFP specific CD4+T cells respectively. LGG-IL2-GFP immunization generated 
significantly higher GFP specific CD8+ T cells (197 ± 27) than LGG-GFP (105 
± 23).  The cytotoxic activity of these cells against a GFP expressing cancer cell 
line, MB49-GFP was examined. The CTL activity in splenocytes isolated from 
mice immunized with LGG-IL2-GFP was about 2 fold greater than in those 
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         a)                                                          b ) 
 















Figure 3.22. IFN- ELISPOT for the analysis of GFP specific CD4+ or CD8+ 
T cells and CTL assay 
a) shows GFP specific CD4+T cell responses on day 80. PBS immunized mice 
splenocytes treated with mitomycin–C cultured alone (column 1); cultured with 
CD4+ T cells enriched from-  PBS immunized mice without (column 2) or with 
GFP (column 6); LGG immunized mice without (column 3)  or with GFP 
(column 7);  LGG-GFP immunized mice without (column 4) or with GFP 
(column 8) and LGG-IL2-GFP immunized mice without (column 5) or with 
GFP (column 9). B) shows GFP specific CD8+T cell responses on day 35. The 
legend is as for CD4+ T cell responses above except that whole splenocytes 
harvested from immunized mice were co-cultured with mitomycin-C treated 
splenocytes and GFP specific CTL peptide .  
C) ) GFP specific CTL responses of splenocytes from mice immunized with 
modified or wild type LGG. Splenocytes (effector cells) from immunized mice 
were pooled 7 days after the last booster administration (day 35) and co-cultured 
with mitomycin C treated MB49-GFP cells and the GFP peptide for 5 days. The 
MB49-GFP cells (target cells) were mixed with effector cells at various E:T 
ratios (1:1, 10:1,and 30:1). Specific lysis was determined by quantitative 
measurements of LDH. * indicates statistical significance from PBS and LGG 
immunized mice and ** indicates statistical significance from PBS, LGG and 
































































































Intranasal immunization with both modified LGG induced GFP specific serum 
IgG, IgA, IgM and SIgA. The fusion of IL2 to GFP resulted in significantly 
increased GFP specific serum IgA and IgG and SIgA titers compared to LGG-
GFP immunization. Lactobacillus delivery of GFP (approximately 0.1 ng) 
resulted in approximately 2.0 g/ml of GFP specific IgG antibodies being 
produced from LGG-GFP, while co-delivery of IL2 and GFP resulted in more 
antibody production namely 3.2 g/ml of GFP specific antibodies.  Our data 
indicates that a low level of secreted IL2 (approximately 20 pg) is sufficient to 
produce significant adjuvant effects (a 1.6 fold increase in antibody production).  
Histopathological examination of lung tissues harvested on 35th and 80th day 
showed no abnormal lung damage happened in nasal immunization of live LGG 
though increased cellular infiltration was observed on 35th day which was 
reduced on 80th day. Histopathological examination may be required to be 
performed 100- 180 days  post primary immunization to rule out the persistence 
of cellular infiltration and chronic lung inflammation. Immunohistochemical 
staining of the lung tissue showed IgA producing B cells at 80th day of post 
primary immunization. Nasal delivery of LGG-IL2-GFP  induced the expression 
of chemotactic factors Interleukin-16 (chemotactic factor for CD4+ T cells), 
chemokine (C-C motif) ligand 25 (CCL25 - chemotactic factor for thymocytes, 
macrophages and DC) and Interferon γ  inducible protein ( IP10- 
chemoattractant for moncytes/macrophages, T cells, NK cells and DC) in lung. 
Moreover, the expression of chemokine (C-C motif) receptor 2 (CCR2) which is 
a receptor for monocyte chemoattractant protein-1, a chemokine which 
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specifically mediates monocyte chemotaxis and CD8a were also upregulated in 
LGG-IL2-GFP imunization. Increased CD8a mRNA expression indicates 
increased recruitment of CD8+ T cells to lungs.   There were increased GFP 
specific CD8 T cells in the recall assay which was significantly increased by 
IL2- GFP nasal delivery.   
 
3.5. Lactobacilli secreting IL15/IL2/IL7 and antigen stimulate bone marrow 
derived dendritic cells and increase antigen specific cytotoxic T 
lymphocytes responses  
The immunomodulatory potential of lactobacilli and its ability as a vaccine 
delivery vehicle are well accepted (Poo et al. 2006; Zegers et al. 1999) in 
infection models.  In a few cancer models, where the cancer expresses a viral 
protein or is induced by bacterial infection Lactobacilli vaccines have been 
shown to be efficacious (Corthesy et al. 2005;  Ho et al. 2005;  Poo et al.  2006). 
One main problem in cancer is the identification of specific antigens. One of the 
best studied examples of a cancer marker is the Prostate specific antigen (PSA) 
which is elevated in prostate cancer. 
Cytokines can potentiate the immune response elicited by vaccines but if 
they promote cytotoxic T lymphocyte (CTL) production as do members of γc 
cytokine family (IL7, IL15, IL21 and IL2), they may be beneficial for tumour 
immunotherapy (Fry et al.  2002;  Ma et al. 2003;  Mueller et al. 2008;  
Pulendran et al.   2004).  IL-2 has demonstrated activity against renal cell, 
melanoma, lymphoma, and leukemia (Niethammer et al. 2001;  Foa et al. 1994). 
IL15 is pivotal in the development and maintenance of antigen specific CD8+ T 
cells and co-injection of IL15 gene with a viral DNA vaccine increased CTL 
responses (Kim et al. 1998).  
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Co-administration of IL15 is known to induce stronger cellular and 
humoral immune responses systemically and mucosally (Stevceva et al. 2006). 
IL7 has a potential role in modulating peripheral T cell expansion and 
proliferation in response to high and low affinity antigens (Fry et al. 2002). IL21 
is more recently identified and in a number of murine tumor models genetically 
modified to secrete IL21 there was tumor regression or rejection but this 
response has been linked to NK cell activation rather than T cells (Di Carlo et al. 
2004; Ma et al. 2003).  Therefore this study was limited to IL2, IL15 and IL7 to 
determine their vaccine adjuvant effect using LGG as the delivery vehicle and 
PSA as the tumor marker. 
 
   3.5.1. Increased antigen production with the pLP500slpA promoter plasmid 
LGG transformed with the pLP500 plasmid with the ldh promoter of L. casei 
upstream of a IL-2-GFP gene fusion produces approximately 1ng of antigen/1.3 
x 109 CFU/ml in total and about 1/5th  of this is secreted. To improve antigen 
production the ldh promoter (523bp) was replaced with the slpA promoter from 
L. acidophilus S-layer protein (McCracken et al. 2000; Savijoki et al. 1997) and 
its secretory sequence (397 bp). Fig 3.23. shows the slpA promoter region and 
signal sequence that were amplified and cloned. The cytokine antigen constructs 
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After transformation, LGG Ery+ positive colonies were selected and their 
growth curves established. Culture supernatants from LGG-S-PSA, LGG-S-IL2-
PSA, LGG-S-IL15-PSA and LGG-S-IL7-PSA were harvested at the late 
exponential phase (approximately after 20-22 hours of culture) and analyzed for 
PSA or cytokine secretion. The antigen was 100% secreted and the PSA or 
cytokine-PSA fusion proteins were in the range of 16 - 19 ng/2 x 109 CFU/ml 
which was approximately 10 fold higher than that produced with ldh promoter. 
The biological activity of IL2-PSA and IL15-PSA fusion proteins were 
measured using a proliferation assay with the IL2 dependent mouse cell line 
CTLL-2. The biological activity of IL2 or IL15 fused to PSA was not different 
from IL2 or IL15 secreted without PSA and identical to the activity of the 
Figure  3.23. Nucleotide sequence of the S-layer protein A promoter 
region of Lactobacillus acidophilus that was amplified and cloned into 
pLP500.  Oligonucleotides slpA FP and slpA RP were used to amplify the 
promoter region. The location of the -35 and -10 signal, ribosome binding site 
and signal peptide sequence are indicated on the sequence.  
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human IL2 standard. 
 
3.5.2. Both recombinant LGG and control LGG efficiently mature DCs 
 Previous studies have shown that Lactobacilli can induce the up regulation of 
co-stimulatory molecules in human and mice DCs (Christensen et al. 2002; 
Veckman et al. 2004). To determine if this response is modulated by the 
cytokines, the BMDC were co-cultured with 100 fold more LGG secreting 
cytokines and antigen and analyzed by flow cytometry (Figure 3.24). All LGG 
treatment up regulated the expression of CD86, CD80, CD83, CD40 and MHC 
class II (Table 3.9). LGG-S-IL15-PSA induced statistically significant up 
regulation of CD80, CD86 and CD40 compared to DC only and DC treated with 



























Figure 3.24.  Lactobacilli induce the maturation of bone marrow derived 
dendritic cells (BMDC). BMDC were incubated with LGG-S or LGG-S-
IL15-PSA at a bacteria to BMDC ratio of 100:1 overnight and stained with 
antibodies to co-stimulatory molecules. Flow cytometry histograms are shown 
for untreated BMDC or BMDC treated with LGG-S or LGG-S-IL15-PSA. The 
numbers indicate the percentage of cells adjusted by subtraction of the 
fluorescence by control matched isotype antibodies. The flow cytometry 
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                                 % surface expression of co stimulatory receptors Treatment 
CD86 CD80 CD83 CD40 MHC II 
BMDC only 
DC+LGG (SlpA) 
DC+ LGG (IL2-PSA) 
DC+LGG (IL15-PSA) 
DC+LGG (IL7-PSA) 
DC+LGG (PSA)  
16.1 ± 1.29 
52.5 ± 2.93 
60.4 ± 6.03 
61.4 ± 6.17 
58.1 ± 2.59 
61.8 ± 3.39 
 
16.5 ±1.98 
32.4 ± 2.86 
29.1 ± 3.54 
39.3 ± 3.22* 
38.3 ± 3.61* 
35.8 ± 2.26 
24.7 ± 2.09 
38.7 ± 3.28 
38.7 ± 3.11 
38.0 ± 1.76 
38.5 ± 2.42 
37.5 ± 1.81 
7.0 ± 0.94 
41.6 ± 2.92 
45.4 ± 3.81 
52.1 ± 2.00** 
46.5 ± 2.03 
47.8 ± 2.02 
53.8 ± 1.71 
67.4 ± 2.34 
67.3 ± 0.9 
68.2 ± 1.77 
68.4 ± 1.20 
68.6 ± 1.37 
* Statistically significant (p<0.05) compared to DC only and DC+LGG (IL2-PSA).  
** Statistically significant compared to DC only, DC+ LGG(SlpA) and DC+LGG(IL2-PSA). 
* Statistically significant (p <  0.05) compared to DC only and DC +  LGG (IL2-PSA). ** Statistically significant compared to DC only,   
DC +  LGG(SlpA) and DC + LGG(IL2-PSA). 
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3.5.3. LGG–S-IL15-PSA induces more IL12p70 production by BMDCs  
 DCs are known to secrete IL12 when cultured with Lactobacillus species 
(Mohamadzadeh et al. 2005). We analyzed the effect of the cytokines on the 
induction of IL12p70 (bioactive IL12) by BMDC. Figure 3.25.a, shows the level 
of IL12p70 produced during BMDC-bacteria co-culture. All the cytokine-PSA 
secreting LGG induced statistically significant IL12 production compared to 
control LGG (LGG-S) or LGG-S-PSA. IL15-PSA secreting LGG induced a 
statistically significant increase in IL12 (about 670 pg/ml) production compared 
with IL2 or IL7-PSA secreting LGG. However, there was no difference in the 
levels of TNFα produced after stimulation of BMDCs by any of the modified 
LGG as seen in Figure 3.25.b. IL15 and IL2-PSA secreting LGG suppressed IL10 
secretion by BMDC and it was statistically significant with IL10 induced by 











































Figure 3.25. Induction of IL12p70, TNFα and IL10 production by BMDCs 
treated with recombinant LGG.  BMDCs were treated with recombinant LGG 
overnight and analyzed for IL10, IL12p70 and  TNFα  by ELISA. * denotes 
statistical significance from DC, DC+ LGG-S and DC+ LGG-S-IL7-PSA. *♦ 
denotes statistical significance from DC, DC+ LGG-S, DC+ LGG-S-IL7-PSA 
and LGG-S-PSA.  ** denotes statistical significance from DC, DC+ LGG-S and  
LGG-S-PSA. *** denotes statistical significance from DC, DC+ LGG-S, DC + 
LGG-S-IL2-PSA, DC+LGG-S-IL7-PSA and LGG-S-PSA. A p < 0.05 is 
statistically significant. Data are represented as mean ± SEM for triplicates of 
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3.5.4. Induction of T cell proliferation and activation by BMDC mediated 
antigen presentation 
DC induce the adaptive immune response by priming T cells to proliferate and 
secrete IL2 or IFNγ.  Priming of T cells depends on antigen presentation by MHC 
I or II complexes on antigen presenting cells. BMDC were incubated overnight 
with either cytokine–PSA secreting or PSA secreting or control LGG. External 
bacteria were killed and cleared and the BMDC were incubated with CFSE 
labeled or unlabeled naïve T cells for 5 days for antigen priming. T cell 
proliferation was observed in co-culture with DCs treated with LGG-S or LGG-S-
































Figure 3.26. Induction of T cell proliferation by DC stimulated with 
lactobacilli. BMDC were treated with LGG-S or LGG-S-IL15-PSA 
overnight at a bacteria to BMDC ratio of 100:1 and then the bacteria were 
killed by gentamycin treatment. The DCs were then co-cultured with CFSE 
labelled naive T cells at a stimulator to responder ratio of 1:100 for 3 days. 
Proliferation of CD4+ or CD8+ T cells were analyzed by flowcytometer. For  
CD8+ T cells proliferation *** denotes statistically significant with 
1,2,3,4,6&7,** statistically significant with 1,2,3,4&7 and statistically 
significant with 1,2,3 &4. For CD4+ T cells proliferation ♦ denotes 














                                          124
 
IL15-PSA secreting LGG induced a high allogeneic CD8+ T cell proliferation 
which was statistically significant with LGG or PSA secreting LGG or IL2/IL7-
PSA secreting LGG treated groups. Though the CD8+ T cells co-cultured with 
LGG-PSA and LGG-IL15 treated DC also demonstrated a high proliferation rate 
compared to other treatment groups, it was not as high as the proliferation 
observed with LGG-IL15-PSA treatment which highlighted the enhanced antigen 
presentation obtained with fusion construct (Figure 3.26).  
LGG itself stimulated DC to activate T cell IL-2 production and this was 
increased in the presence of antigen and was further enhanced by the presence of 
IL15. LGG-S-IL15-PSA treated DC induced T cells to secrete a higher level of 
IL2 (p < 0.05) than LGG-S (Figure 3.27.a). All PSA/cytokine-PSA secreting LGG 
treated DC cultured with T cells elicited significant IFNγ production (p < 0.05) 
compared to LGG-S. IFN production induced by LGG-S-IL15-PSA was 
significantly more than that produced after stimulation with LGG-S-IL2-PSA or 
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Figure 3.27. LGG itself stimulated DC to activate T cell IL-2 production and 
this was increased in the presence of antigen and was further enhanced by 
the presence of IL15. LGG-S-IL15-PSA treated DC induced T cells to secrete a 
higher level of IL2 (p < 0.05) than LGG-S (a). All PSA/cytokine-PSA secreting 
LGG treated DC cultured with T cells elicited significant IFNγ production (p < 
0.05) compared to LGG-S. IFN production induced by LGG-S-IL15-PSA was 
significantly more than that produced after stimulation with LGG-S-IL2-PSA or 
LGG-S-PSA (b).  
* denotes statistical significance (p < 0.05) from untreated DC-T co-culture and 
** denotes statistical significance from untreated DC-T and LGG -S treated DC-
T cells co-culture. Data are represented as mean ± SEM of experiments
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3.5.5. Antigen specific cytotoxicity assay 
  To determine the functional activity of T cells the T cells were harvested after 5 
days of co-culture and incubated with the target tumor cells MB49-PSA or control 
MB49 cells. The LDH activity was measured in the supernatant after 5 hours 
incubation. DC primed T cells (with or without bacterial stimulation) showed a 
non-specific cytotoxic effect on control MB49 (about 30 - 40%), figure 3.28 (a)  T 
cells primed with DC that had been stimulated with PSA or cytokine–PSA 
secreting bacteria demonstrated a higher cytotoxic effect on MB49-PSA cells 
(about 50 - 70%), figure 3.28 (b). LGG-S-IL15-PSA treated DC primed T cells to 
kill significantly more MB49-PSA cells than LGG-S-IL2-PSA (p < 0.05) as seen 
in figure.3.28 (b). To determine if the fusion protein of IL15and PSA was as 
effective as IL15 and PSA secreted singly, LGG expressing each gene singly were 
also produce. Interestingly, LGG-S-IL15-PSA (fusion protein) treated DC primed 
T cells showed a higher cytotoxic effect on MB-49-PSA or MB-49 than LGG-S-
IL15 + LGG-S-PSA treated DC primed T cells as seen in figure 3.28.(c). 
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LGG secreting 
Figure 3.28. Recombinant LGG stimulated DC efficiently prime naïve T cells and   
generate antigen specific CD8+ T cells. 
 
a)  and b) T cell mediated cytotoxicity on MB49 or PSA secreting MB49  target cells 
respectively. Target cells were added to 5 days DC-T cell co-cultures and LDH activity 
was measured in the supernatant after 5 hours of incubation. % of cytotoxicity was 
calculated from LDH activity. c) LGG-S-IL15-PSA or LGG-S-IL15+LGG-S-PSA 
treated DC primed T cell mediated cytotoxicity on target cells MB49PSA.  
DC stimulated overnight with LGG-S-IL15-PSA or LGG-S-IL15+LGG-S-PSA were 
co-cultured with naïve T cells for 5 days and target cells MB49 PSA (clear) or MB 49 
















































































































































Improved antigen production was seen in LGG using the slpA promoter and 
secretory signal and that cytokines especially IL15 enhanced antigen presentation 
and activation of T cells. The cytotoxic T cells produced by DCs primed with 
LGG secreting PSA or cytokine PSA fusion proteins specifically recognized 
tumour cells secreting PSA. 
All the antigens produced were secreted unlike LGG transformed with the 
PLP500 plasmid with the ldh promoter, where most of the antigen produced 
remained within the bacteria.  IL15-PSA or IL2–PSA secreting LGG reduced 
IL10 production by DC, IL7 did not, but all three resulted in increased IL12p70 
production. However, the T cell response did not correlate with differences in 
IL12 or IL10 production. 
LGG-S-IL15-PSA treated DC showed high IFNγ production and CTL 
response on target cells indicating efficient antigen presentation to T cells. The 
increased antigen specific cytotoxicity rendered by the T cells primed with DC 
that had been stimulated with IL15-PSA secreting LGG was statistically 
significant from combined stimulation with IL15 or PSA secreting LGG. Thus our 
data indicate that LGG as a promising antigen delivery vehicle and that IL15 is a 
good vaccine adjuvant especially when administered as fusion protein with 
antigen. It also indicates that formation of the fusion protein induces a better 
response.  
                             *Denotes statistical significance (p<0.05) from untreated DC-T and LGG-S treated 
DC-T cells co-culture, *♦ denotes statistical significance from DC cultured with T 
cells or DC cultured with T cells after stimulation with LGG-S, LGG-S-IL2-PSA 
and LGG-S-PSA. ♦ denotes statistical significance from DC cultured with T cells 
or DC cultured with T cells after stimulation with LGG-S and LGG-S-PSA. Data 
are represented as mean ± SEM of experiments performed independently twice in 
triplicates.  
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3.6. Cross talk between LGG treated neutrophils and dendritic cells and its 
effect on DC activation and antigen presentation  
After intranasal immunization we observed neutrophils recruitment to the lungs. 
Neutrophils are effective phagocytic scavengers and the first line of defense 
against invading microbes. During infections, polymorphonuclear leukocytes are 
the first cell type to arrive to the infection site and upon encountering bacteria, 
neutrophils release the generation of reactive oxygen intermediates, preformed 
lytic enzymes and inflammatory mediators to kill the bacteria. Infected neutrophils 
are programmed to die by apoptosis and subsequently are removed by 
macrophages or dendritic cells which are also chemoattracted to the infection site. 
At the site of inflammation activated neutrophils and DCs are shown to interact 
positively through Mac-1/DC-SIGN molecules expressed by neutrophils and 
dendritic cells respectively.  
Even after the clearance of the bacteria at the infection site, live or apoptotic 
neutrophils could transfer the antigen to DC allowing the latter to stimulate the T 
cells to secrete IL2 or IFNγ.  In intranasal immunization, neutrophils would 
internalize the recombinant LGG and transfer the antigen to DC to render the 
antigen specific immune response. In this study, we analyzed the cross talk 
between LGG treated neutrophils and dendritic cells and its effect on DC 
activation and antigen presentation to T cells. 
 
3.6.1. IL10 and TNFα predominantly produced in LGG stimulated 
neutrophils culture. 
Bone marrow derived neutrophils were treated with IL15-PSA or PSA 
secreting LGG or LGG-S for 18hours. Culture supernatants were analyzed for 
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IL12p70 or IL10 or TNFα. Lactobacilli stimulated neutrophils produced 
bioactive IL12, IL10 and TNFα (Table  3.10). 
 
Table 3.10. Cytokines produced from neutrophils on LGG treatment for 18 
hours 
                   level of cytokines (pg/ml) Treatment 
IL10 IL12 p70 TNFα 
Neutrophils only 
 








1632.8 ± 129.38* 
 
1601.4 ± 133.48 
 
1401.4 ± 61.32 
 
 
19.4 ± 13.66 
 
117.3 ± 5.37 
 
131.0 ± 20.36 
 
123.5 ± 24.56 
14.4 ± 4.57 
 
1314.0 ± 66.49 
 
1357.0 ± 99.27 
 
1391.0 ± 89.85 
 
Data represent mean ± standard deviations  
* Statistically significant (p < 0.05) compared to neutrophils treated with LGG-
S-PSA or neutrophils only. 
 
3.6.2. Induction of T cell activation by bone marrow derived neutrophil 
(BMN)      mediated antigen presentation  
Neutrophils induce the adaptive immune response by activating T cells to secrete 
IL2 or IFNγ.  Unlike the DC, neutrophils stimulated with recombinant 
lactobacilli did not show a higher level of MHC II, rather they showed a higher 
level of MHC I expression. MHC I expression on unstimulated BMN was about 
37% whereas all recombinant LGG stimulated BMN showed the expression in 
the range of 64 - 67%. BMN were incubated for 18 hours with either IL15–PSA 
secreting or PSA secreting LGG or control LGG. External bacteria were killed 
and cleared and the BMDC were incubated with allogeneic T cells for 2 days for 
activation. IL2 produced from LGG-S-IL15-PSA or LGG-S-PSA  treated 
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neutrophils induced T cells was not significantly different from LGG-S 
stimulated neutrophils – T cell co-culture as seen figure 3.29.a.  However LGG-
S-PSA or LGG-S-IL15-PSA treated neutrophils induced a higher level of IFNγ  
(p < 0.05) than LGG-S. IFN production induced by LGG-S-IL15-PSA was 
significantly more than that produced after stimulation with LGG-S-PSA (p < 
0.05)   as seen in figure 3.29.b. 
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Unstimulated neutrophils or overnight stimulated neutrophils with LGG-S or 
LGG-S-IL15-PSA or LGG-S-PSA were co-cultured with allogeneic T cells for 2 
days. After 2 days culture supernatants were harvested and analyzed for IL2 (a) 
or IFNγ (b). *denotes statistically significant and ʌ denotes statistical significance 
from unstimulated neutrophils or LGG-S treated neutrophils – T cells co-culture 
or LGG-S-PSA treated neutrophils-T cells co-culture. (p<0.05). Data are 
represented by the mean ± SEM in each group. Data are representative of three 
different experiments. 
 
3.6.3. Impact of LGG stimulated neutrophils on DC activation 
We investigated neutrophils-DC crosstalk in response to LGG. For the 
neutrophils treatment LGG-S and LGG-S-IL15-PSA were used. Neutrophils 
were stimulated with LGG-S or LGG-S-IL15-PSA for 2 hour. After extracellular 
bacteria were killed by gentamycin treatment and subsequent PBS wash, cells 
were incubated with BMDC for 16 hours. For control, neutrophils or BMDC 
were stimulated with rLGG for 2 hours and incubated for 18 hours in fresh media 
after gentamycin treatment and PBS wash. We analyzed whether LGG 
stimulated neutrophils could activate immature DC.  
Co-stimulatory molecules: CD86, CD80, CD83, CD40 and MHC II were 
significantly up regulated on DC in all LGG stimulated neutrophils-DC co-
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Table 3.11. LGG treated neutrophils upregulate co-stimulatory molecules 
on  DC 





























3.69 ± 3.2 
 
65.4 ± 1.2* 
 
73.9 ± 3.2* 
 
 
72.55 ± 0.9* 
 
 
76.91 ± 3.1* 
 

















































Data represent mean % of cells ± standard deviations  




3.6.4. LGG treated neutrophils differentially affect cytokine production by 
DC Direct interaction of LGG with BMDC or neutrophils produced  higher 
IL12p70 or IL10 respectively. LGG-S-IL15-PSA stimulation induced 
significantly higher level of IL12 than that produced by LGG-S.  However LGG 
stimulated neutrophils downregulate IL12p70 and increase IL10 production from 
BMDC in BMDC-neutrophils co-culture. This up regulated IL10 or 
downregulated IL12 production from BMDC induced by LGG stimulated 
neutrophils was significantly different from IL10 or IL12 produced from 
neutrophils or BMDC that were directly stimulated with LGG (figure 3.30. a&b).  
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TNFα was highly produced from DC or neutrophils upon LGG stimulation. 
LGG-S or LGG-S-IL15-PSA induced almost the same level of TNFα from DC 
in direct stimulation. But in indirect stimulation through neutrophils, TNFα 
production was enhanced or suppressed depending on whether LGG-IL15-PSA 
or LGG-S was used  as seen in figure 3.30.c.   
Unstimulated DC produced a high level of TGFβ by itself. Upon LGG 
stimulation, TGFβ production was significantly reduced from DC and 
interestingly, neutrophils could elevate TGFβ production when co cultured with 
DC. The level of TGFβ production from DC co-cultured with neutrophils which 
had been stimulated with LGG-S or LGG-S-IL15-PSA was significantly 
inhibited compared to DC co cultured with untreated neutrophils. (Figure 
3.30.d).  Moreover, TGFβ production from LGG-S or LGG-S-IL15-PSA treated 
neutrophils-DC co-culture was statistically significant from neutrophils or DC 
individually stimulated with LGG-S or LGG-S-IL15-PSA respectively. 
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DC DC  
Figure 3.30. Bioactive  IL12 
or  IL10 or TNFα and or 
TGFβ levels in LGG treated 
BMN or BMDC or LGG 
treated BMN-BMDC co 
culture . 
 
BMN  or BMDC were treated 
with LGG-S or LGG-S-IL15-
PSA  for 2 hours before the 
bacteria were killed and the 
treated BMN co cultured with 
BMDC overnight. Culture 
supernatants were harvested and 
analyzed for IL12p70 (a) or 
IL10 (b) or TNFα (c) and or 
TGFβ (d).  Data represents 
three separate experiments. 
Data are represented by the 
mean ± SEM in each group. 
* denotes statistical ignificance,  
^ denotes statistically ignificant 
with all groups. P value  < 0.05.    
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3.6.5. DC co-cultured with recombinant LGG treated neutrophils elicit T 
cells to produce anti-inflammatory cytokines 
We investigated whether the DC mediated T cell antigen presentation through 
neutrophils could be different from direct antigen presentation. In direct antigen 
presentation, DC mediated antigen presentation was more efficient than 
neutrophils mediated presentation with respect to IL2 or IFNγ production. 
However, LGG-S not LGG-S-IL15-PSA treated neutrophils mediated indirect 
antigen presentation in DC induces a significantly higher IL2, which was 
statistically significant from LGG-S treated DC mediated direct antigen 
presentation. But IFNγ from T cells in direct antigen presentation was not 
different from neutrophils mediated indirect antigen presentation  as seen in 
Figure 3.31. a&b.  
Direct DC mediated antigen presentation actually suppressed TGFβ production 
which is in contrast with enhanced TGF β production observed in neutrophils 
mediated antigen presentation. DC mediated antigen presentation to T cells after 
culture with neutrophils engenders an anti-inflammatory milieu which was 
represented by a significantly higher TGFβ and IL10, Figure 3.31 c & d. 
 
                                                                                                                                    





























































































































1 0 0 0


































Figure 3.31.  Cytokine production 
by neutrophils mediated direct or 
indirect antigen presentation 
through DC to allogeneic T cells. 
  
BMN or BMDC were treated with 
LGG-S or LGG-S- IL15-PSA  for 2 
hours and treated BMN were co-
cultured with BMDC overnight 
followed by addition of allogeneic 
T cells and incubated for 48 hours. 
Culture supernatants were 
harvested and analyzed for IL2 (a);   
IFNγ (b);  IL10(c)  and TGFβ (d).  
 
Data represents two separate 
experiments. Data are represented 
by the mean ± SEM in each group.  
 
*denotes statistically significant 
 (P < 0.05). 
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3.6.6. Study of antigen specific cytotoxic T cells generated by neutrophil 
indirect antigen presentation through DC 
The differential cytokine profile observed in neutrophil antigen presentation  
through DC may influence antigen specific T cell cytotoxicity. After bacteria 
treated neutrophils-DC co-culture, DCs were enriched using CD11c microbeads 
and co-cultured with naïve T cells for 5 days to generate PSA specific T cells. 
Then target tumour cells MB49-PSA or control MB49 were added to study the 
cytotoxic effect. PSA specific cytotoxicity was calculated based on the LDH 
released to the culture supernatant. LGG-IL15-PSA or LGG-PSA treated DC 
were able to generate a high number of antigen specific T cells as the % of 
cytotoxicity observed in DC mediated direct antigen presentation is higher (40.9 
± 0.78 or 31.0 ± 1.09)  compared to neutrophils mediated indirect DC antigen 
presentation (23.8 ± 1.77 or 21.7 ± 1.55). Another interesting feature, 2 hours 
LGG-IL15-PSA treated DC elicited a significant cytotoxic effect compared to 
LGG-PSA treated DC (Fig 3.32 a&b). 
 




































Figure 3.32.  Antigen specific cytotoxicity of the T cells generated by co-
culture with DC treated with recombinant LGG for 2 hours (a) or DC 
enriched from overnight culture of DC+ LGG treated neutrophils (b).   
Neutrophils or DC treated with LGG-S (striped) or LGG-IL15-PSA (shaded) or 
LGG-PSA (cross striped) or left untreated (clear) and used for DC co-culture 
followed by T cell presentation assay or T cells co-culture respectively. PSA 
secreting (MB49-PSA) or control mouse urothelial cancer cell line (MB49) was 
used as target cells. Data are represented by the mean ± SEM in each group. * 
Statistically significant (p < 0.05) compared to untreated or treatment with LGG-




LGG treatment with neutrophils did produce bioactive IL12 and a high level of 
IL10 and TNFα.  Moreover, LGG treated neutrophils did not induce any of the 
co-stimulatory molecules or MHC II expression, but only showed elevated 
expression of the MHC I molecules. In antigen presentation even though 
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overnight stimulated LGG efficiently induced allogeneic T cells proliferation, 2 
hours stimulated neutrophils elicited 1.05 or 1.49 ng of IFNγ which are slightly 
higher than 0.70 or 1.11 ng produced in overnight stimulation with LGG-S or 
LGG-S-IL15-PSA treatment respectively.  Increased expression of co-
stimulatory molecules on DC in neutrophils-DC co-culture clearly showed 
bacteria treated neutrophils could deliver the maturation signals to immature 
DC. However, LGG treated neutrophils stimulate higher IL10 but not IL12 from 
DC. High IL10 along with increased production of TGFβ was observed in DC-
LGG treated neutrophils co-culture. However it did not affect the T cell 
presentation very much that was characterized by high IL2 and IFNγ which were 
almost the same level as the DC or much higher than neutrophils mediated direct 
antigen presentation. But the cytotoxic effect elicited by the T cells generated by 
co-culturing with recombinant LGG treated DC  was higher than that  with the 












                                          141
3.7. Improvement of antigen production in LGG using different promoters  
Though high antigen production was not considered as a prerequisite for 
colonizing lactic acid bacteria in mucosal immunization, high antigen producing 
bacteria will enhance the antigen specific immune induction. Our initial 
experiment done with LGG transformed with pLP500-IL2-GFP plasmid which 
has lactate dehydrogenase promoter (ldh) promoter, expressed only about 1-2ng 
antigen. Later experiments done with the replacement of ldh with S-layer protein 
A (slpA) promoter in the plasmid increased the antigen expression to 20ng. 
However it was not as high as previously reported using lactobacillus brevis S-
layer signal (Savijoki et al. 1997).  Recombinant protein production normally 
depends on the strength of the promoter of the plasmid, plasmid copy number 
and the target strain. The knowledge of stable or strong promoters in LGG was 
limited since LGG’s complete genome sequence is not known and LGG is 
infrequently used as a vaccine vehicle to express foreign protein.  In this study 
two strategies were attempted to improve the protein expression as seen in 
Figure 3.33. 
1. To express the protein using a tandem promoter contruct. 
 An enhanced gene expression under two tandem promoters was reported in 
Lactococcus lactis ( Wei et al, 2002).  We cloned two promoters, ldh or  slpA 
separately or tandemly  by integrating the core ldh promoter without ribosome 
binding site with slpA promoter. 
2. To use the phosphoglycerate mutase (pgm) promoter of L. acidophilus. 
Promoter pgm was cloned with its secretory signal peptide sequence in pLP500 
plasmid after  ldh promoter was removed by restriction digestion. 
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Mouse IL2 cDNA was cloned in either plasmid and the efficiency of protein 
expression was analyzed. 
 
Figure 3.33. Construction of plasmids that secrete murine IL2 under 
different promoters. a) or b) are IL2 secreting plasmids under ldh or slpA 
promoters.  c) IL2 secreting plasmid under ldh-slpA tandem promoter. d) IL2 
secreting plasmid under putative promoter of pgm gene. S.S- secretory sequence 
of slpA promoter. TSS-transcription start site. RBS- ribosome binding site. S.S 
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3.7.1. Construction of pLP500ldh-slpAp  plasmid  
The core promoter region without ribosome binding site of ldh (figure.3.34) was 
amplified from L. caesei genomic DNA by PCR using the primers listed in 
Table. 2.2 and cloned in pLP500-slpAp  plasmid to give  pLP500ldh- slpAp .  
GAATTCAGAT CTACTAGAGG …….                                 ……. AAACAGGATTCACAA
GTCTT GCTGTAGTAA GGCTCGACGC CATTTTTTGA CAATGGCAAAATCATGAAA
AAGTCTATCAAATTTGTTTCA GGGAATTGATAATGTGTTAT ACTCAACGTG AAA
TGCAGTTTGCATGCACATAAA 




3.7.2. Construction of pLP500pgmp plasmid 
A putative promoter of pgm gene of L. acidophilus (Figure 3.35) was amplified  
from genomic DNA by PCR using the primers listed in Table. 2.2 and cloned in 
to Pldh removed pLP500 plasmid to generate pLP500pgmp.  
 
Figure 3.34. Nucleotide sequence of the Lactobacillus caesei ldh core promoter 
without RBS. Oligonucleotides Pldh FP and Pldh RP were used to amplify the 
promoter region. The location of the -35 and -10 signal are indicated on the 
sequence.  
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TGCGACAAGTAATAAA….                     …..TCTTAGGAGA 










3.7.3. Estimation of IL2 expression or secretion in recombinant  LGG 
Murine IL2 cDNA was amplified from pBud- IL2 plasmid by PCR using the 
primers listed Table 2.1 and cloned in frame with secretory signal sequence of 
slpA gene and the recombinant plasmid was electroporated to LGG.  After 
transformation, LGG Ery+ positive colonies were selected and their growth 
curves established. Culture supernatant or bacterial pellet  from LGG-IL2 
(pLP500ldhp-IL2), LGG-IL2 (pLP500slpAp-IL2), and LGG-IL2 (pLP500pgmp-
IL2) were harvested after 20 -22 hrs of culture (late exponential phase) for IL2 
estimation and  LGG-IL2 (pLP500ldh-slpAp-IL2) were harvested at 24 – 26 hrs 
of culture since it grows  a bit slower than the other recombinant LGG. At this 
time the bacterial CFU was approximately 2 x 109 /ml. Protein was extracted 
from bacterial cell lysate and analyzed for IL2 along with the supernatants.  IL2 
was  100% secreted in LGG-IL2 (pLP500slpAp-IL2), LGG-IL2 (pLP500ldh-
slpAp-IL2) and there was only 20% of IL2 was secreted in LGG-IL2 
Figure 3.35. Nucleotide sequence of the putative pgm promoter of  Lactobacillus 
acidophilus with coding sequence for the first 39 amino acids.  Oligonucleotides 
pgmFP and pgm RP were used to amplify the desired region. The location of the 
RBS and putative translation start site are indicated on the sequence.  
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(pLP500ldhp-IL2). There was no IL2 secretion  observed in LGG-IL2 
(pLP500pgmp-IL2).  IL2 secretion from 2 x 109 CFU LGG was about 96 ng or 
20 ng under ldh-slpA tandem promoter or slpA promoter respectively and the 
total  production (intracellular and secretory) of IL-2 under ldh promoter was 
about 1.76 ng (Figure 3.36). Only 1/5 of the total protein produced was secreted 
which was about 407 pg/ml. 
 










Figure 3.36. IL2 secretion or expression from LGG.  
Bacterial lysate or culture supernatants were screened for mouse IL2 and 




slpA promoter of L. acidophilus was recognized well in LGG and produced a 
high IL2 production. ldh promoter, though it was a strong constitutive promoter 
in L. caesei it gave only 2 ng of IL2 production. So the efficiency of the 
recognition of the ldh promoter region may be host dependent. However when 
expressed as a tandem promoter with slpA, ldh produced a higher level of IL2 
which was almost 5 times more than that was produced by slpA promoter alone.  
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Putative promoter of L. acidophilus pgm gene was considered as a strong 
constitutive promoter and the heterologous protein expression  under this 
promoter in L. acidophilus was reported before. But we did not see IL2 secretion 
under this promoter in LGG. So the pgm promoter may not have been 
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LAB  based vaccines are being explored for prophylaxis or treatment for 
infections or allergic diseases. Because of their GRAS status, they can be used 
without any reservation as it is unlikely that they could induce any adverse 
effects except the possibility of septicaemia in severely immuno-compromised 
recipients (Schlegel et al. 1998). Among LAB, Lactococcus lactis and L. 
plantarum are widely studied as vaccine delivery vehicles. LGG has rarely been 
analyzed as a vaccine delivery vehicle. However, the beneficial effects of LGG 
in cancer has been studied in murine models (Seow et al. 2009; Lim et al. 2002). 
Its intrinsic anti-cancer effect; ability to adhere strongly and colonize mucosal 
sites makes this microbe an attractive candidate for evaluation as an antigen 
delivery vehicle.  
 
4.1. Oral or nasal co-delivery of IL-2 and an antigen, the green fluorescence 
protein, by Lactobacillus rhamnosus GG results in increased antigen 
specific humoral immune response with enhanced CD8 and CD4 T cells 
responses 
GFP has been expressed in bacteria to track microbes in the host after 
immunization.  In our study we used GFP as a model antigen and also to track 
the bacteria in the intestines or lung after oral and nasal immunization 
respectively. The oral route is the main infection site for many pathogens. Orally 
administered mucosal vaccines induce secretory IgA production (Mestecky et al. 
2008) and contain the infections at its initial stage by preventing the replication 
of pathogens. In this present  study, LGG secreting GFP or IL2-GFP as a fusion 
protein both were shown to be able to elicit both mucosal and systemic humoral 
responses after oral immunization in mice which was in agreement with a study 
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conducted by Steidler et al (1998). Oral immunization of LGG elicited a 
sustained mucosal IgA induction and ex vivo culture of the intestines also 
showed a higher IgA level 56 days after the last booster immunization. 
Intranasal immunization with both modified LGG induced GFP specific serum 
IgG, IgA, IgM and SIgA. While comparing the immune induction in oral and 
nasal immunization, nasal immunization produced a higher specific humoral or 
cellular immune response. The advantage of intranasal over oral route in 
mucosal immunization has been demonstrated with recombinant Lactococcus 
lactis (Cortes-Perez et al. 2007). Intransal immunization with lactococci 
displaying human papillomavirus type 16 (HPV-16) E7 antigen at its surface 
(LL-E7) and secreting IL12 induced a higher antigen specific IgG or IgA in 
serum or gastric lavage fluid (GAL) respectively and enhanced E7 antigen 
specific IFNγ secreting T cells in spleen more than observed in oral 
immunization. IL2 coexpression with GFP enhanced immune response after 
both in oral and nasal immunization. The fusion of IL2 to GFP resulted in 
significantly increased GFP specific serum IgA and IgG compared to LGG-GFP 
immunization in both oral and nasal immunization. Steidler et al (1998) have 
previously shown the adjuvant effects of cytokines produced by modified 
Lactococci were observed if they were secreted. Several studies also have been 
done to elucidate the significance of IL2 or IL4 in the induction of B cell 
proliferation and Ig secretion (Franz et al. 1991; Valle et al. 1991; Forman et al. 
1991). Addition of IL2 to cultures of B cells activated with anti Ig or CD4+ T 
cells results in enhancement of antibody secretion (Croft et al. 1991; Boom et al. 
1988; Abraham et al. 1992) and moreover in oral immunization, IL2 is known to 
stimulate CD3є- IL2Rα+ cells at the gut lamina propria to secrete IL5 which 
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helps B cells to produce IgA (Kuraoka et al. 2004). IL2 co-expression correlated 
with a significant accumulation of IgA+ B cells in NALT and CLN after nasal 
immunization. Clonal expansion of IgA+B cells could occur in the NALT prior 
to the dissemination of sensitized lymphocytes to mucosal and non mucosal 
lymphoid tissues (Kiyono et al. 2004; Hameleers et al. 1991; Tilney et al. 1971). 
Lactobacillus delivery of GFP (approximately 0.1 ng) resulted in approximately 
0.3 or 2.0 g/ml of GFP specific IgG antibodies being produced from LGG-
GFP, while co-delivery of IL2 and GFP resulted in more antibody production 
namely 0.52 or 3.2 g/ml of GFP specific antibodies after oral or nasal 
immunization respectively. In contrast delivery of 10g of purified Tat protein 
either alone or with macrophage-activating lipopeptide-2 [MALP-2] or Freund’s 
adjuvant produced 7, 68 and 173 g/ml respectively of specific IgG antibodies 
after nasal immunization (Borsutzky et al. 2003). This clearly highlights the 
efficacy of Lactobacilli and IL2 as adjuvants and our data indicates that a low 
level of secreted IL2 is sufficient to produce significant adjuvant effects namely 
a 1.73 fold (oral) and a 1.6 fold (nasal) increase in antibody production.  
The increased level of anti-LGG antibodies was not as great as the 
increase in GFP antibodies produced by the IL-2 fusion protein. LGG-IL2-GFP 
induced higher GFP specific serum IgG or sIgA over LGG specific antibodies 
than LGG-GFP in oral and nasal immunization. Though nasal immunization 
produced higher GFP specific IgG and IgA, IL2 mediated specific antibody 
induction (GFP specific Ab over LGG specific Ab) was higher in oral 
immunization. In oral immunization LGG-IL2-GFP elicited 2.5 or 1.33 fold 
higher specific IgG or IgA respectively compared to 1.33 or 1.2 folds induced 
after nasal immunization.  
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          Thus Lactobacilli with IL2 co-expression are excellent delivery vehicles 
as they do not evoke a strong antibody response against themselves. The CD8 
recall response was similar to that reported by Poo et al. (Poo et al.  2006). After 
oral immunization with 5 x 109 cfu L. casei expressing an E7 antigen on the 
surface they obtained about 500 plus IFN- secreting CD8+ T cells in contrast to 
the 187  31 GFP specific IFN- secreting T cells produced with 1 x 108cfu of 
LGG-IL2-GFP immunization in this study. The differences between our studies 
may be due to the strain difference (Shaw et al. 2000; Oliveira et al. 2006) and 
the mode of the delivery of the antigen i.e. surface bound rather than secreted or 
intracellular expression.  
             Microarray and semi quantitative PCR analyses showed significantly 
increased gene expression of CCR2, IP-10 and CD8a in mice lungs immunized 
with LGG-IL2-GFP.  Interferon inducible protein of 10 kDa (IP-10 or CXCL10) 
is known as one of the potent chemokines that regulate the migration of effector 
T lymphocytes. Vaccination with DC2.4 cell line transduced with IP-10 gene 
generated strong E7-specific CD8+ T cell immune responses and mediated a 
stronger anti-tumor effects against an E7- expressing murine tumor cell (TC-1) 
(Kang et al. 2009). Increased IP-10 expression in LGG-IL2-GFP immunized 
mice lung was observed with elevated expression of CD8a suggesting that IP-10 
would have probably induced the migration of CD8+ T cells. CCR2 expression 
was reported to be up-regulated following growth factor deprivation and its 
ligand CCL2 has a role in the proliferation of CD8+ functional T cells in 
response to IL-2 or to secondary antigenic challenges (Diaz-Guerra et al. 2007). 
However, the underlying mechanism for the concomitant expression of CCR2 
not CCL2 with CD8a expression in LGG-IL2-GFP immunized mice lung is not 
                                          152
clear. Nonethless gene expression analyses of the lung suggested LGG-IL2-GFP 
immunization preferentially increased CD8+T cells. 
                IL2 was initially described as a negative regulator  of the memory 
CD8+ T cell response since IL2 was reported to cause activation induced cell 
death (AICD) among T cells (Marks-Konczalik et al. 2000) and injection of 
anti-IL2 antibody decreased the numbers of memory phenotype CD8+ T cells in 
animals by affecting dividing cells (Ku et al. 2000). But, recent reports have 
demonstrated the positive role of IL2 on memory CD8+ T cells as injection of 
anti-IL2 antibody increases the biological activity of IL2 possibly through the 
formation of immune complexes (Boyman et al. 2006). In this study it was 
showed that IL2 secreted at low level (approximately 20 pg) is sufficient to 
produce significant CD8+ T cell response. The mechanism of enhanced CD8+ T 
cell response mediated by low level of IL2 was not clear. It is posible that fusion 
with GFP increases IL-2 survival in vivo (half-life normally about 10 mins) and 
this ensures that though very low levels are expressed it is sufficient to enhance 
the responses to the antigen (Melder et al. 2005; Smith et al. 2006).  Another 
possibility is that IL2 physical linkage to antigen may have led to an enhanced 
MHC- class I presentation of antigen as observed for the E7-IL2 DNA vaccine 
(Lin et al. 2007) which elicited an enhanced CD8+ T cell immune response. 
Hence, it is therefore postulated that lactobacilli stimulation through TLR2 on T 
cells may further enhance the T cell response by IL2 linkage since TLR2 
induced IFNγ production was enhanced in the presence of IL2 (Imanishi et al. 
2007). In the experiments conducted in the present study, culturable LGG were 
isolated from MLN or NALT in large numbers 24hrs after oral or nasal 
immunization respectively. Viable IL2-GFP secreting LGG might engage TLR2 
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on T cells at MLN or NALT and act in synergy with IL2 (IL2-GFP) to modulate 
the IFNγ secretion capacity of T cells (Cottalorda et al. 2009).  More studies will 
need to be carried out to determine the detailed mechanism that causes the 
improved CD8+ T cell response. 
The M cells located in the FAE are believed to be a route for pathogen 
invasion into the circulation and for presentation of antigens to the immune 
system (Neutra et al. 1999). The adherence of lactobacilli to FAE was observed 
in a previous study (Edelman et al. 2002) and is in line with earlier report of 
association of certain lactobacilli with Peyer's patches of the mouse (Plant et al. 
2001). However the possible interaction of lactobacillus with M cells has not 
been reported till now.  In  this study, it was demonstrated for the first time the 
M cells mediated LGG uptake in intestinal villus. After being transported 
through M cells, bacteria are engulfed by DC or macrophages in the sub-
epithelial dome (SED) region underlying the FAE and transported to MLN 
(Ruedl et al. 1996). Macpherson et al (2004) reported after oral administration of 
109 Enterobacter cloacae, 1000 or 800 CFU bacteria were recovered from MLN 
at 24 or 48hrs respectively and no bacteria were recovered from splenocytes. In 
agreement with their observation, there was a high number of live LGG were 
isolated from MLN in this current study although there were also many live 
LGG (178 ± 41) isolated from spleen after 24hrs of immunization. However the 
number of bacteria were reduced after 48hrs (15 ± 4) and completely cleared in 
1 week with the oral administration of 1 x 108 CFU LGG-IL2-GFP.  Their 
finding with gastric lavage of E. cloacae showed that commensal bacteria are 
prevented from entering the systemic immune compartment like spleen as they 
are efficiently killed by macrophages. However this present study indicate that 
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their finding with E. cloacae may not be applicable to all commensal bacteria. A 
previous study showed that LGG are resistant to the intracellular killing activity 
of macrophages (Asahara et al. 2003).  Moreover, L. rhamnosus and L. caesei 
have been sometimes reported as the causes for infective endocarditis (Harty et 
al. 1994). Though Lactobacillus bacteremia was a very uncommon condition, it 
was believed to occur due to translocation of the bacteria across intestinal 
mucosa (Antony et al. 1996). So the questions are still unanswered whether the 
LGG-loaded DC are only confined within the mesenteric lymph nodes  and  
whether CD11c - CD11b+ intestinal murine macrophages are able to kill LGG 
effectively in vivo. These are avenues for further studies to redefine the 
compartmentalization of the immune responses to lactobacilli.   
In summary, the results of this study clearly demonstrate the beneficial 
effects of low levels of IL2 when expressed as a fusion protein with an antigen 
and conveyed by Lactobacilli, to elicit enhanced local and systemic immune 
responses to the antigen, as well as the safety and efficacy of Lactobacilli 
secreting cytokines. It is likely that the immune response to antigens delivered 
by LGG could be increased by either the delivery of more Lactobacilli (Ho et al. 
2005; Russell et al. 1996) or by using plasmids with different promoter strengths 
so as to increase antigen production (Narita et al. 2006; Sorvig et al. 2005) or 
even using co-expression of different cytokines.  
  4.2. Lactobacilli secreting IL15/IL2/IL7 and antigen stimulate bone marrow 
derived dendritic cells and increase antigen specific cytotoxic T 
lymphocytes responses 
  There was an improved antigen production by LGG using the slpA promoter and 
secretory signal and that cytokines especially IL15 enhanced antigen 
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presentation and activation of T cells. The cytotoxic T cells produced by DCs 
primed with LGG secreting antigen or cytokine antigen fusion proteins 
specifically recognized tumour cells secreting PSA. 
            It was previously reported that the L. acidophilus S layer promoter (P-
slpA) was three times more effective than the most active homologous L casei 
promoter (Boot et al. 1996)  and it directed efficient transcription in L 
rhamnosus as well  (McCracken et al. 2000). The S-layer proteins are efficiently 
secreted as well, so the promoter elements as well as the signal sequence were 
used to produce LGG that secrete antigens. All the antigens produced were 
secreted unlike LGG transformed with the PLP500 plasmid with the ldh 
promoter, where most of the antigen produced remained within the bacteria.   
      
  L. reuteri reduced and L. casei induced up regulation of CD86 (Christensen  et 
al. 2002).  LGG stimulated human monocyte derived DCs at a low bacterial 
dose (5:1 – bacteria : DC ratio) showed only moderate expression of co-
stimulatory molecules and produced low levels of cytokines ( Veckman et al. 
2004). However a high dose (100 : 1 – bacteria : DC ratio) of LGG can have 
stimulatory effects on DC maturation and antigen presentation.  
                 The present study showed LGG stimulation alone on BMDC produced  
high levels of IL-12 without CD40L help. IL12 production was also induced in 
DC by stimulation with Toxoplasma gondii extract or lipopolysaccharide 
without CD40L help (Reis e Sousa et al. 1997). CD40L has been known to 
synergize with soluble tachyzoite antigen (STAg) of T. gondii or CpG DNA to 
induce high levels of IL-12 production by DC (Schulz et al. 2000).  DC from 
IL15 knock out mice (IL15-/-) are known to produce low IL-12p70 and 
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exogenous supply of recombinant IL15 will increase IL-12p70 production but 
not in IL15R-/- DC  (Ohteki et al. 2001). In agreement with these findings 
BMDC stimulated with LGG-S-IL15-PSA produced a significantly higher 
amount of IL12p70.  
               T cells incubated with LGG-S-IL15-PSA treated DC showed high IFNγ 
production and CTL response on target cells indicating efficient antigen 
presentation to T cells. IL-15 itself is able to activate DC in vivo and in vitro, to 
enhance the ability of DC to stimulate Ag-specific CD8+ T cells (Ohteki et al. 
2001; Pulendran et al. 2004; Mattei et al. 2001). The mechanism by which IL15 
mediates enhanced antigen presentation has not been defined but evidence in the 
literature points to several possible pathways. Firstly, enhanced antigen 
presentation could be a consequence of increased IL12 production engendered 
by LGG-S-IL15-PSA treatment (Christensen et al. 2002). The second possible 
mechanism for increased antigen specific CD8 + T cells expansion could be 
through trans presentation of IL15 by DC.  IL15 can up regulate IL-15αR 
expression on DC and IL15αR can efficiently trans present the bacteria secreted 
IL15 to IL-2Rβ/ c heterodimeric receptor on responding cells to initiate 
signaling (Wu et al. 2008) which up-regulates anti-apoptotic signals such as Bcl-
2, promoting T cell survival. The IL15/IL15R complex can recycle through the 
endosomal vesicles for several days (Dubois  et al. 2002) and so the signalling 
activity would persist even after removal of the bacteria by gentamycin 
treatment. No evidence exists for such a mechanism for IL7, but stimulated DC 
do produce IL7.  Expression of IL7R on B or T cells lineage was reported (Sudo 
et al. 1993) but its expression on DC has not been defined yet.  
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            Another possible mechanism is the effect of IL15 on the regulation of the 
antigen processing machinery (APM) in DC. Tumour cells down regulate APM 
expression in DC and recombinant IL15 administration restores MHC class I 
APM component expression in DC (Tourkova et al. 2005). Trauma has also 
been shown to suppress splenic DC antigen presentation and exogenous IL15 
can attenuate this response. (Kawasaki et al. 2009).   
PSA specific cytotoxic effect on target cells in T cell presentation with 
LGG-S-IL2-PSA stimulated DC was not significantly different with LGG-S-
PSA stimulation. IL2 role on DC has not been clearly defined as yet. DC from 
IL-2–/– mice are impaired in their ability to induce allogeneic CD4+ T-cell 
proliferation (Granucci et al. 2001). DC treated with IL2Rα antibody and LPS 
caused a reduction in IL-12, IL-1, TNF- , IL-6, and IFN-  production and 
decreased the DC ability to prime allogeneic CD4+ T cells compared with 
stimulation with LPS alone (Mnasria et al. 2008). Hence, LGG-S-IL2-PSA 
treated DC may have a role in inducing CD4+ not CD8+ T cells. 
   T cells incubated with LGG-S-IL7-PSA treated DC showed CTL response on 
target cells which is significantly different from LGG-S or LGG-S-PSA 
treatment. High IL7 was reported to promote not CD4+ but CD8+ T cell 
proliferation and  IL-7 signalling down regulates MHCII expression in IL7Rα+ 
DC that contribute to diminished CD4+T cell homeostatic proliferation 
(Guimond et al. 2009). Further study may be required to investigate whether 
IL7 secreted by LGG-S is enough to induce the preferential proliferation of 
CD8+ T cells which would be observed as higher cytotoxic effect on target 
cells.  
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   In summary, the data in this study indicate that LGG as a promising antigen 
delivery vehicle and that IL15 or IL7 is a good vaccine adjuvant.  
 
   4.3. Cross talk between LGG treated neutrophils and dendritic cells and its 
effect on DC activation and antigen presentation 
In agreement with previous reports on microbes treatment with neutrophils  
(Bennouna et al. 2003), LGG treatment with neutrophils did not produce a vey 
high bioactive IL12 rather it produces a high level of IL10 and TNFα. Moreover, 
LGG treated neutrophils did not induce any of the co-stimulatory molecules or 
MHC II expression, but only showed elevated expression of the MHC I 
molecules. Human polymorphonuclear neutrophils (PMN) require prior 
treatment of IFNγ, GM-CSF and IL3 to express MHC II molecules (Gosselin et 
al. 1993). Even after IFNγ and GM-CSF treatment, not all antigens were known 
to be processed and elicit specific T cells proliferation presented in a MHC II 
restricted manner. Super antigen but not tetanus toxoid (TT) treated PMN 
stimulated specific T cell proliferation (Fanger et al. 1997; Radsak et al. 2000). 
In mice, neutrophils purified from peritoneal exudate cells (PEC) were shown to 
express MHC II molecules expression and neutrophils pulsed with OVA323-339 
peptide induced specific CD4+T cells proliferation (Culshaw et al. 2008). 
However, we did not observe increased MHC II expression in bone marrow 
derived neutrophils (BMN) after LGG treatment. It may suggest bone marrow 
derived neutrophils may have a different MHC expression profile compared to 
PEC neutrophils.  Potter et al (2001) reported neutrophils process the exogenous 
bacteria in alternate MHC I pathway and present the antigen to T cells. It was 
presumed that  following phagocytosis, LGG also would be processed in the 
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alternate MHC I pathway since it elicited only the expression of MHC I 
molecules. After  antigen presentation for 2 hours neutrophils elicited 1.05 or 
1.49 ng of IFNγ which are slightly higher than 0.70 or 1.11 ng produced in 
overnight stimulation with LGG-S or LGG-S-IL15-PSA treatment respectively. 
The reduced IFNγ production in overnight stimulated neutrophils suggests the 
suppressive effect rendered by higher IL10 production (Fiorentino et al. 1991). 
Increased expression of co-stimulatory molecules on DC in neutrophils-DC co-
culture clearly showed bacteria treated neutrophils could deliver the maturation 
signals to immature DC. However, LGG treated  neutrophils stimulate higher 
IL10 but not IL12 from DC which is an opposite effect seen in  BCG (Morel et 
al. 2008) or Toxoplasma  (Bennouna et al. 2003) treatment with neutrophils. 
High IL10 along with increased production of TGFβ in DC-LGG treated 
neutrophils co-culture generates an anti-inflammatory milieu. IL10 produced in 
neutrophils-DC co-culture was positively correlated with the concentration of 
the bacteria used to stimulate neutrophils (data was not shown). After 
encountering a  high number of bacteria, neutrophils may undergo apoptosis, 
(Ocana et al. 2008) perhaps TRAIL/Apo-2L mediated as seen in BCG 
stimulation (Kemp et al. 2005) and apoptotic neutrophils may be phagocytosed 
by DC (Stark et al.  2005). The uptake of apoptotic cells by phagocytosis could 
trigger a powerful anti inflammatory signal (Savill  et al. 2000; Stuart  et al. 
2002) like increased release of IL10 (Steinman et al. 2000), TGF-β and 
inhibition of IL12 and IL8 (Voll et al. 1997; Kim et al. 2004). Apoptotic 
neutrophils bind to protein S in serum which interact with TAM receptor 
(protein tyrosine kinases-TYRO3, AXL and MER) (Lemke et al. 2008) 
expressed on DC or macrophage (McColl et al. 2009) that augment phagocytic 
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removal of apoptotic neutrophils.  Further investigation is required to examine 
whether the apoptosis would be induced in neutrophils with LGG stimulation 
(1:100 neutrophils: LGG ratio) and the level of TAM receptor expression on DC 
in DC – neutrophils (stimulated with LGG) co-culture.   
The immunosuppressive environment observed in neutrophils-DC co-
culture did not affect the T cell presentation that was characterized by high IL2 
and IFNγ which were almost the same level as the DC or  much higher than 
neutrophils mediated direct antigen presentation. Recombinant LGG treated 
neutrophils provided antigen specificity to DC when it was co-cultured with DC 
and also rendered a moderate cytotoxic effect in T cell presentation. This 
ensures the efficacy of LGG based antigen delivery in inducing immune 
response through neutrophils alone in the absence of direct bacteria-DC 
encounter.  Further study may be required to analyze the proportionate antigen 
specific T cells generated in neutrophils mediated direct or indirect antigen 
presentation and the inhibitory mechanism of inflammatory cytokines 
production in DC that phagocytose the apoptotic neutrophils.   
In summary, the present study demonstrates the effect of LGG in 
neutrophils- dendritic cells cross talk, highlights the balancing effect of LGG 
treated neutrophils on DC to shut down the inflammatory response. However 
further studies may be required to demonstrate the LGG treated neutrophils-DC 
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 4.4. Improvement of antigen production in LGG using ldh-slpA tandem  
promoter  
 For high protein production, a strong promoter is necessary. Improvement by 
genetic engineering to induce high protein production in the target strain have 
been carried out by modifying the promoter sequence ( Estrem et  al. 1998; 
Jensen and Hammer et al. 1998;  Solem and Jensen et al. 2002 ). Protein 
production was shown to have increased in recombinant bacteria under two or 
three tandem promoters in contrast to one alone in Bacillus subtilis. (Widner et 
al. 2000). This strategy has been applied in Lactococcus lactis for the expression 
of staphylokinase variant gene (sakXH) under the control of two tandem 
promoters (P32-PlacA) and showed improved protein production (Wei et al. 
2002). In our study we developed a protein expression system using LGG as the 
host strain and constructing two tandem promoters, ldh and slpA for protein 
expression. The expression of α amylase was improved under the control of ldh 
promoter that was integrated with the untranslated leader sequence (UTLS) of 
the slpA gene from L. acidophilus (Narita et al. 2006). The structure of the 
UTLS is deduced to be important in the mRNA stability (Daguer et al. 2005; 
Fournier et al. 2001) and in our study we used the whole promoter sequence of 
the slpA gene including UTLS coupled with ldh core promoter. The RBS of the 
slpA promoter was used in this study instead of the RBS of the ldh to prevent 
the destruction of the structure. The fusion expression system increased the IL2 
production to almost 5 folds compared to IL2 secreted under slpA promoter 
alone.  
In another strategy to improve the IL2 secretion we used a putative 
promoter of pgm and its secretory signal sequence including coding sequence 
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for 39 aminoacids for pgm protein to generate pgm-IL2 fusion protein. 
Phosphoglycerate mutase (PGM), an important enzyme in the glycolytic 
pathway, catalyzes the transfer of a phosphate group between the 2 and the 3 
positions of glyceric acid. Lactobacilli which grow better in anaerobic 
environment (Pant et al. 1996) may have a high expression of pgm. 
Mohamadzadeh et al reported the oral administration of L. acidophilus mediated 
delivery of Bacillus anthracis protective antigen-dendritic cells targeting fusion 
protein ( PA-DC pep ) under the expression of L. acidophilus pgm promoter 
generated protective immunity against B. anthracis lethal challenge. Though we 
followed the same strategy, the transformed LGG did not result in IL2 
production. We surmise that the pgm promoter may not have been recognized in 
LGG.  
4.5. Conclusion 
In most of the studies in which Lactobacilli have been explored as vaccine 
candidate in either oral or nasal route, bacteria used for immunization were more 
than 108 CFU. In the present study 108 CFU LGG was used and demonstrated  
the antigen specific humoral and cellular immune induction. Despite the low IL2 
level expressed in LGG as IL2-GFP fusion protein, it convincingly enhanced 
GFP specific immune induction. Strikingly, the enhanced immune induction has 
lasted even 50 days after the booster immunization. While comparing oral or 
nasal immunization, nasal immunization showed better immune response. Live 
bacterial administration were mostly discouraged in nasal immunization as live 
bacteria may cause lung infection and some times may result in pneumonia. 
However because of the GRAS status Lactobacilli administration did not 
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produce any lung damage except scattered cellular infiltration observed after 
few days of immunization.  
         L. acidophilus slpA promoter enhanced the protein expression more than 
10 folds in LGG. Moreover slpA secretory signal was well recognized in LGG 
and showed almost 100% extracellular delivery of heterologous protein. Protein 
expression under SlpA-ldh tandem promoter improved the protein expression to 
5 or 50 folds more than the protein expression under individual slpA or ldh 
promoter respectively.  IL15 co-expression with tumour antigen PSA enhanced 
antigen presentation and showed a higher antigen specific cytotoxic effect 
followed by IL7 co-expression.  It also demonstrated an enhanced DC mediated 
antigen presentation to T cells and induced a high CD8+ T cell proliferation. 
Recombinant LGG treated neutrophils interact positively with DC to produce T 
cell presentation and antigen specific cytotoxic effect though it has not been as 
high as direct DC antigen presentation.  However it needs further investigation 
to characterize the anti-inflammatory immune induction in DC-neutrophils 
mediated T cell presentation.  
Seow et al (2009) reported that intravesical administration of LGG recruited 
large numbers of neutrophils and macrophages to the tumor site and showed 
better cure rate than BCG (89% vs 77%) which is considered as gold standard 
for bladder cancer immunotherapy.  This cytotoxic effect may be enhanced 
further with the intravesical instillation of recombinant LGG that express 
specific tumour antigens like BLCA-4 (Van Le et al. 2004) since recombinant 
LGG can induce neutrophils mediated antigen specific cytotoxic effect.  
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   4.6. Future directions 
It has been shown convincingly in this series of experiments that LGG could 
deliver the antigen efficiently and induce specific immune response. The 
beneficial effect of cytokine-antigen co-expression in enhancing antigen specific 
cytotoxic effect has been also demonstrated. However, the enhanced antigen 
presentation and cytotoxic effect in common gamma chain cytokine – antigen 
expressing LGG treated DC needs to be shown in vivo and the mechanism for 
the enhanced immune response after immunization with fusion proteins also 
needs to be unravelled. As such further research should be aimed at the 
following: 
1.  Future experiments should determine how IL2 in pg levels preferentially 
produces a high CD8+ T cell response. It may be extended to see the effect of 
high IL2 (in ng to µg level) in the induction of CD8+T cell response.     
2.  Though the cellular infiltration observed in 35th day of post primary nasal 
immunization was reduced on 80th day, some inflammatory cells were still 
present and thus it may be required to examine the infiltration or inflammatory 
changes up to 100-180 days to rule out LGG mediated persistent or chronic lung 
inflammation. If the latter is present than LGG vaccines should only be 
delivered via the oral route. 
 3. LGG-S-IL15-PSA treated DC showed high IFNγ production and CTL 
response on PSA secreting tumour cells indicating efficient antigen presentation 
to T cells in vitro. In future experiments, IL-15 mediated enhanced antigen 
presentation has to be confirmed in vivo by analyzing whether mucosal 
immunization of IL15-antigen fusion protein secreting LGG efficiently kill the 
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tumour cells compared to immunization with antigen alone or with other 
cytokine-antigen fusion protein in an animal tumour model.  
4. Future experiments may also be focussed on neutrophil mediated in vivo 
indirect antigen presentation to T cells and the analysis of T cell mediated 
antigen specific cytotoxic effect in the murine bladder cancer model by 
intravesical instillation of recombinant LGG.  
5. In neutrophils-DC cross talk study, DC mediated antigen presentation to T 
cells through  neutrophils engenders an anti-inflammatory milieu which was 
represented by a significantly higher TGFβ and IL10.  Future study may be 
focussed on the T cell phenotype which secrete TGFβ.  
6. Increased antigen production may be imperative for inducing a high antigen 
specific immune response. Future studies should explore the possibilities of a)  
stronger promoters and b) to design the cassette to express the antigen and 
cytokine under different promoters, so that their expression will be manipulated 
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